| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Scilex Holding Company$9.48
+0.28 (+3.04%)
C 43Pipeline Score Fair Value Biotech · Commercial
Market Cap
51.88 M
EPS
-40.58
P/E Ratio
-
Value Trade
320.42 K
SEC Financials
Q1 2026Dilution Risk
Revenue
8.61 M
R&D Expenses
3.21 M
Operating CF
-1.11 M
Total Assets
293.63 M
Total Liabilities
547.71 M
Equity
-249.22 M
D/E Ratio
12,345
-4.53 %
Week
-11.71 %
1 Month
-22.17 %
3 Month
-67.36 %
6 Month
-98.23 %
5 Year
-98.23 %
All Time
Cash Data
Cash Position
8.18 M
Monthly Burn
369.00 K
Runway
20.7 mo
Burn Trend
SEC Filing
May 20, 2026
Overview
Volume
83.14 K
52 Week Range
4.20 - 34.27
% held by Insiders
17.56 %
% held by Institutions
10.27 %
Enterprise Value
150.03 M
Total Shares
8.49 M
Short %
2.9 %
Float Shares
6.29 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Scilex Holding Company
322Total events
2Upcoming
81Tier-1 (high impact)
2020 – 2036Coverage
Upcoming catalysts 2
Event history 320
Jul 7, 2026
▲Partnership / LicenseCorporate
Semnur signs binding term sheet for $100M strategic investment from iHolding Group LLP
Jul 6, 2026
◆Equity OfferingCorporate
Signing of binding term sheet for $100M strategic investment from iHolding Group LLP
Jun 29, 2026
●Quarterly UpdateCorporate
Payment date for Dream Bowl Token dividend (within 60 days after record date)
Jun 23, 2026
◆Other Regulator MilestoneEx-US Regulatory
Dream Bowl I Meme Coin tokens to list on Biconomy Exchange
Jun 15, 2026
May 22, 2026
▲Quarterly UpdateCorporate
Board approved dividend of Semnur common stock to Scilex stockholders
May 5, 2026
▲Partnership / LicenseCorporate
ACEA Therapeutics and ACEA Pharma entered into definitive agreement with Phoenix Asia Holdings for acquisition of ACEA Pharma
Apr 20, 2026
●Quarterly UpdateCorporate
Board approved dividend of Dream Bowl I Meme Coin Tokens with record date April 30, 2026
Q2 2026
◆AcquisitionCorporate
Closing of acquisition of ACEA Pharma by Phoenix Asia Holdings expected by end of Q2 2026
Drug Pipeline Intelligence
C43
Pipeline Score $50M
Pipeline ValueFair Value
Valuation Signal4
Drugs Scored1.0x
rNPV / MCap Top 62%
Micro Cap (rank 347 of 911)
Percentile RankScilex Holding Company carries a moderate pipeline score (43/100), with $1.3B risk-adjusted pipeline value, led by SP-103 in Moderate to Severe Acute Lower Back Pain (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SP-103 Small molecule | Moderate to Severe Acute Lower Back Pain | Phase 2 | NCT05096494 | 17% | $999M | COMPLETED | 75 | - | - | May 30, 2023 | - | Jul 6, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SP-102 Fast Track | lumbosacral radicular pain | — | 2025-05-16 | clear clinically meaningful separation between SP-102 and placebo in multiple with-in subject endpoints Read More | Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL Read More | |
SP-102 Fast Track | lumbosacral radicular pain | — | 2025-05-16 | clear clinically meaningful separation between SP-102 and placebo in multiple with-in subject endpoints Read More | Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL Read More | |
SP-102 Fast Track | lumbosacral radicular pain | — | 2025-05-16 | clear clinically meaningful separation between SP-102 and placebo in multiple with-in subject endpoints Read More | Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SCLX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SCLX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SCLX▲ +23%on this news
Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
Semnur Pharmaceuticals has signed a binding term sheet with iHolding Group for a proposed $100 million investment. This funding aims to support the advancement of Semnur's pipeline, particularly the Phase 3 clinical program for SEMDEXA™. The investment is contingent upon due diligence and regulatory approvals, marking a significant step for Semnur's growth and innovation in non-opioid pain therapies.
Read more →SCLXScilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026
Scilex Holding Company announced that its Dream Bowl I Meme Coin tokens began trading on the Biconomy Exchange on July 6, 2026. This move is expected to provide liquidity and broaden the distribution of the tokens among eligible equityholders. The Biconomy Exchange is recognized for its security and extensive trading volume, which may benefit the token's market presence.
Read more →SCLXScilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP
Scilex Holding Company has signed a binding term sheet for a proposed $100 million investment from iHolding Group LLP. This investment will support Scilex's strategic growth, including product development and acquisitions. The agreement is contingent upon customary due diligence and regulatory approvals. iHolding aims to bolster Kazakhstan's role in the global healthcare sector.
Read more →SCLX▼ -26%on this news
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026
Scilex Holding Company has announced that its Dream Bowl I Meme Coin tokens will be listed on the Biconomy Exchange starting June 23, 2026. This listing is expected to provide liquidity and enable widespread distribution of the tokens to eligible equity holders. Scilex continues to focus on developing non-opioid pain management products.
Read more →SCLXScilex Holding Company (“Scilex”) Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
Scilex Holding Company has confirmed the payment date of June 15, 2026, for the dividend of Semnur Pharmaceuticals, Inc. common stock to eligible holders of Scilex securities. The ex-dividend date is set for June 16, 2026. This announcement provides clarity for investors regarding the dividend process and highlights Scilex's ongoing commitment to developing non-opioid pain management products.
Read more →SCLX▲ +5.7%on this news
Scilex Holding Company (“Scilex”) Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
Scilex Holding Company announced that it will pay a dividend of Semnur Pharmaceuticals common stock to eligible shareholders on June 15, 2026. Each eligible holder will receive one share of Semnur stock for every share of Scilex stock held as of the record date of June 1, 2026. However, the payment is subject to change if the Board decides to revoke the dividend or alter the payment date. Scilex holds approximately 186 million shares of Semnur, intending to distribute around 14 million shares to its shareholders.
Read more →SCLXScilex Holding Company (“Scilex”) Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026
Scilex Holding Company announced a dividend of Semnur Pharmaceuticals common stock for its shareholders, with a record date set for June 1, 2026. Each holder of Scilex common stock will receive one share of Semnur stock for each share they own. The board retains the right to change the record date and payment conditions, reflecting ongoing financial assessments.
Read more →SCLXScilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited
Scilex Holding Company announced a definitive agreement for its subsidiaries, ACEA Therapeutics and ACEA Pharma, to be acquired by Phoenix Asia Holdings. The deal involves the transfer of 100% equity interests of ACEA Pharma for $1 billion in shares. The acquisition is set to close by the end of Q2 2026, pending regulatory approvals.
Read more →SCLX▲ +5.4%on this news· ran to -24% by day 3shared move
Scilex Holding Company Announces Its Board of Directors Approved May 26, 2026 as the Payment Date of the Previously Announced Dividend of Dream Bowl Meme Coin I Tokens to Record Holders of Common Stock and other Eligible Equity Securities as of the Record Date of April 30, 2026
Scilex Holding Company has announced that its board approved May 26, 2026, as the payment date for a dividend of Dream Bowl Meme Coin I tokens to eligible stockholders. Each holder will receive five tokens for each share of common stock. The company plans to list these tokens on the Biconomy exchange to enhance liquidity. However, the Board retains the right to change the payment date or revoke the dividend.
Read more →SCLX▲ +21.8%on this newsshared move
Dear Scilex Holding Company Stockholders and other holders of Scilex Holding Company Securities: This letter is being furnished to you as a holder of certain securities of Scilex Holding Company, a Delaware corporation (
Scilex Holding Company has announced a dividend of Dream Bowl Meme Coin I tokens for holders of its common stock, warrants, convertible notes, and Series A Preferred Stock as of April 30, 2026. Shareholders must set up a digital wallet with Datavault AI Inc. and complete an Opt-In Agreement to receive the tokens, which are set to be distributed starting May 26, 2026. This dividend is described in the materials sent to all record holders, and more information can be accessed via the company's dedicated Dividend Website.
Read more →SCLXScilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026
Scilex Holding Company has announced a dividend of Dream Bowl I Meme Coin Tokens for its stockholders, with a record date set for April 30, 2026. Eligible holders will receive five tokens per share of common stock. The distribution is subject to the Board's approval and requires holders to set up a digital wallet. The tokens are intended for personal use and do not confer any ownership rights.
Read more →SCLX▼ -6%on this news
KASOWITZ LLP Daniel A. Saunders (SBN 161051) DSaunders@kasowitz.com Robert W. Bosslet (SBN 278027) RBosslet@kasowitz.com 1801 Century Park East, Suite 1830 Los Angeles, California 90067 Telephone: (424) 288-7900 Facsimil
Scilex Holding Company has initiated legal action against multiple defendants, including Marc Wade and Bank of New York Mellon, alleging fraud in a loan agreement that resulted in the sale of pledged securities. The lawsuit claims a conspiracy where the defendants intended to misappropriate stock and manipulate the market value of the shares. Scilex asserts that it has suffered significant financial damage due to these actions, leading to additional accusations of default against the company. The case highlights serious allegations of securities fraud and misrepresentation.
Read more →SCLX▼ -6%on this news
Scilex Holding Company Files Federal Securities Fraud Lawsuit Seeking Recovery of Approximately Ninety-Six (96) Million Misappropriated Collateral Shares of Datavault AI, Inc. from Marc Wade, The St. James Bank & Trust Company Ltd., Omega & Corinth Group Ltd., The Bank of New York Mellon Corporation, and Related Parties
Scilex Holding Company has filed a federal lawsuit against Marc Wade and several financial institutions, alleging the unauthorized sale of approximately 96 million shares of Datavault AI, Inc. The lawsuit details a breach of the stock loan agreement, where shares were sold without consent, leading to substantial financial harm for Scilex. The company is pursuing damages exceeding $100 million, as well as recovery of the misappropriated shares. The allegations indicate potential market impact due to the volume of shares traded unlawfully.
Read more →SCLXScilex Holding Company Announces $20 Million Strategic Investment in Quantum Scan Holdings, Inc., Targeting Trillion-Dollar Preventive Diagnosis and Prognosis Markets
Scilex Holding Company has announced a $20 million strategic investment in Quantum Scan Holdings, Inc. This investment aims to support Quantum Scan's development of advanced diagnostic technologies targeting preventive diagnosis and prognosis markets. The collaboration is expected to enhance healthcare accessibility and efficiency, aligning with Scilex's strategic priorities in non-opioid pain management.
Read more →SCLX▲ +7.3%on this news
Scilex Holding Company Appoints Kasowitz LLP as Litigation and Intellectual Property Counsel
Scilex Holding Company has appointed Kasowitz LLP, led by Marc Kasowitz, as its litigation and intellectual property counsel. This strategic move aims to bolster Scilex's legal capabilities in complex commercial and patent litigation as it advances its non-opioid pain management products. The appointment is seen as crucial for protecting the company's intellectual property and enhancing shareholder value.
Read more →SCLX▼ -8.2%on this news
Scilex Holding Company Confirms Dream Bowl 2026 Meme Coin Claim Process on December 24, 2025 Drop by Datavault AI Inc.
Scilex Holding Company has confirmed the process for claiming Dream Bowl 2026 Meme Coins starting December 24, 2025, utilizing Datavault AI's blockchain technology. Eligible shareholders of record as of November 25, 2025, can participate in the token distribution, which aims to integrate digital assets with sports and shareholder benefits. This initiative represents Scilex's innovative strategy in the evolving digital asset space, promising to boost shareholder engagement and interest.
Read more →SCLXScilex Holding Company Announces Closing of Previously Announced Second Tranche Investment in Datavault AI Inc., Completing Its Two-Tranche Equity Financing in Datavault AI Inc.
Scilex Holding Company has successfully closed the second tranche of its investment in Datavault AI Inc., solidifying a strategic partnership. This investment included purchasing a pre-funded warrant for 263,914,094 shares of Datavault AI, valued at approximately $583.3 million. The closing followed stockholder approval at Datavault's annual meeting and is expected to strengthen collaboration in the realm of Real World Asset tokenization moving forward. Scilex's commitment to expanding its operations aligns with its focus on non-opioid pain management products.
Read more →SCLXScilex Holding Company Announces Closing of Exercise of Warrants for $20.3 Million Gross Proceeds
Scilex Holding Company has successfully closed the exercise of existing warrants, generating approximately $20.3 million in gross proceeds. The company issued new warrants allowing the purchase of additional shares at a reduced exercise price. The funds will be allocated for working capital and general corporate purposes, supporting Scilex's focus on non-opioid pain management solutions.
Read more →SCLXScilex Holding Company Announces Exercise of Warrants for $20.3 Million Gross Proceeds
Scilex Holding Company has announced the exercise of existing warrants, resulting in gross proceeds of approximately $20.3 million. The exercise involves warrants for 428,572 and 475,824 shares at prices of $38.50 and $22.72, respectively. The offering is expected to close on November 25, 2025, and the funds will be used for working capital and general corporate purposes.
Read more →SCLXScilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.
Scilex Holding Company announced an upcoming distribution of Dream Bowl 2026 Meme Coins by Datavault AI to its common stockholders. This distribution is a token of appreciation for Scilex's partnership with Datavault AI. The distribution will occur on November 25, 2025, but is subject to changes by Datavault AI's Board of Directors regarding the record and payment dates.
Read more →SCLXScilex Holding Company Announces that the Board of Directors of Datavault AI Inc. Has Approved the Distribution of a Dream Bowl 2026 Meme Coin to All Eligible Scilex and Datavault AI Stockholders of Record and Set a Record Date of November 25, 2025
Scilex Holding Company announced that Datavault AI Inc. will distribute a Dream Bowl 2026 Meme Coin to eligible stockholders on record as of November 25, 2025. This digital collectible aims to enhance engagement and recognition of ownership among shareholders. The event will culminate in a championship at AT&T Stadium on January 11, 2026, featuring various competitions.
Read more →SCLX▲ +10.4%on this news
Scilex Holding Company Announces Worldwide Exclusive License for Tokenization and Monetization of Real-World Asset (RWA) in Genomic, DNA Data, Diagnosis, Therapeutics Products, Genetic and Drug information from Datavault AI
Scilex Holding Company has announced a worldwide exclusive license with Datavault AI to utilize its AI-driven technology for tokenizing and monetizing biotech assets. This license aims to establish a Biotech Exchange platform, potentially transforming the pharmaceutical industry. Scilex anticipates significant financial opportunities through tokenization, with a commitment to pay $10 million in licensing fees and potential milestone payments of up to $2.55 billion.
Read more →SCLX▲ +7.8%on this news· ran to +19% by day 1shared move
Scilex Holding Company Announces the Sponsorship of Dream Bowl 2026 and Set a Record Date of November 14, 2025 for Its Shareholders to Receive Dream Bowl 2026 Meme Coin Distributed by DataVault AI
Scilex Holding Company has announced its sponsorship of the Dream Bowl 2026, with a record date set for November 14, 2025, for shareholders to receive a meme coin. This digital collectible will serve as a token of participation and will be airdropped to shareholders. The event, culminating on January 11, 2026, will feature elite athletes and e-sports competitions.
Read more →SCLX▲ +5.1%on this news
Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase
Scilex Holding Company has announced the completion of the first tranche of its warrant repurchase from Oramed Pharmaceuticals, acquiring 3.13 million warrants for $13 million. This transaction is part of a larger agreement allowing Scilex to repurchase a total of 6.5 million warrants. The company retains the option to repurchase the remaining warrants by the end of 2025.
Read more →SCLXScilex Holding Company Announces Closing of Previously Announced Initial Tranche Investment in Datavault AI
Scilex Holding Company has announced the closure of the initial tranche of its $150 million investment in Datavault AI, acquiring 15 million shares at an effective price of $0.5378 per share. The remaining shares will be issued in a second tranche, pending stockholder approval. This investment aligns with Scilex's strategy to enhance its portfolio in non-opioid pain management solutions.
Read more →SCLXScilex Holding Company Announces $150 Million Strategic Bitcoin Investment in Datavault AI
Scilex Holding Company has announced a $150 million investment in Datavault AI to enhance its supercomputing infrastructure and expand data exchanges. This strategic move aims to capitalize on the growing biotech data monetization market, projected to reach $30-50 billion by 2024. Scilex will receive shares in Datavault and gain board representation, aligning their resources with Datavault's advanced technologies.
Read more →SCLXScilex Announces Closing of Previously Announced Non-Dilutive Value Enhancing Transaction with an Institutional Investor for the Exchange of $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held by Scilex Holding Company for $200 Million in Bitcoin
Scilex Holding Company has completed a significant transaction, exchanging $200 million of common stock from its subsidiary Semnur Pharmaceuticals for an equivalent amount in Bitcoin. This strategic move is aimed at enhancing Scilex's financial resources and supports its focus on developing non-opioid pain management products. The transaction involved 12.5 million shares of Semnur stock.
Read more →SCLXScilex Holding Company Announces It Has Entered into a Memorandum of Understanding with Biconomy.com to Collaborate on Future Cryptocurrency Strategies and Treasury Management
Scilex Holding Company has signed a non-binding Memorandum of Understanding with Biconomy.com to explore cryptocurrency strategies and treasury management. This collaboration aims to leverage Biconomy's platform for global cryptocurrency trading and establish a treasury management strategy that balances security and yield. The partnership is expected to enhance Scilex's digital asset monetization.
Read more →SCLX▼ -12.5%on this newsshared move
Scilex Holding Company Announces Signing of a Securities Purchase Agreement with an Institutional Investor to Exchange $200 Million of Common Stock of Semnur Pharmaceuticals, Inc. Held By Scilex Holding Company for $200 Million in Bitcoin
Scilex Holding Company has signed a Securities Purchase Agreement to exchange $200 million of common stock from its subsidiary, Semnur Pharmaceuticals, for an equivalent amount in Bitcoin. The deal involves the sale of 12.5 million shares at $16 each and is expected to close around September 23, 2025. This strategic move reflects Scilex's commitment to diversifying its financial portfolio and engaging in cryptocurrency markets.
Read more →SCLXSemnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination
Scilex Holding Company announced the successful closing of its business combination with Denali Capital Acquisition Corp. The new entity will operate as Semnur Pharmaceuticals, Inc., focusing on non-opioid pain management solutions. This transition is expected to enhance growth and accelerate the development of their product candidate, SP-102, aimed at treating chronic pain.
Read more →SCLXScilex Holding Company (Nasdaq: SCLX) Announces Its Majority-Owned Subsidiary, Semnur Pharmaceuticals, Inc. (“Semnur”), and Denali Capital Acquisition Corp. Have Entered into a Purchase Agreement with an Investor for a $20 Million Private Placement at $16.00 per share and Jaisim Shah, Scilex’s CEO and President, Will be Dedicated to Semnur on a Full Time Basis to Rapidly Advance SP-102 to Regulatory Approval and Commercialization for the Treatment of Lumbosacral Radicular Pain (LRP)/Sciatica
Scilex Holding Company, through its subsidiary Semnur Pharmaceuticals, announced a $20 million private placement to support the advancement of SP-102, a treatment for lumbosacral radicular pain and sciatica. The shares will be sold at $16.00 per share post-business combination with Denali Capital Acquisition Corp. Following the resignation of Jaisim Shah as CEO of Scilex, he will focus full-time on Semnur, which aims to accelerate SP-102's development. The arrangement highlights Scilex's commitment to non-opioid pain management therapies.
Read more →SCLX▲ +18.8%on this news
Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex
Scilex Holding Company announced that the SEC has declared effective the registration statement related to the proposed business combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, a majority-owned subsidiary of Scilex. An extraordinary general meeting for Denali shareholders is set for September 3, 2025, to vote on the merger. Upon completion, the combined entity will be renamed Semnur Pharmaceuticals, Inc., focusing on advancing non-opioid pain management therapies. However, approval for listing the new company's stock on Nasdaq is still pending, with no guarantees of meeting the required standards.
Read more →SCLXScilex Holding Company Announces Deferral of Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from May 2, 2025 to a future date to be determined by the Board
Scilex Holding Company has announced a deferral of the record date for its previously declared dividend on preferred stock, originally set for May 2, 2025. The new record date will be determined at the discretion of the Board of Directors, who also reserve the right to revoke the dividend entirely. This decision may affect investor sentiment and confidence, as the Board retains control over the timing and potential payment of the dividend.
Read more →SCLX▼ -7.2%on this news
Scilex Holding Company Announces Publication on GLOPERBA Dosing Adjustments in Peer-Review Journal
Scilex Holding Company announced a significant publication regarding dosing adjustments for GLOPERBA® in a peer-reviewed journal. GLOPERBA® is the first liquid oral formulation of colchicine, offering enhanced safety for gout patients, particularly those with renal impairment. The study presents specific dosing recommendations aiming to optimize treatment outcomes and reduce toxicity risks. This initiative positions Scilex to fulfill unmet medical needs in pain management for patients with complex health conditions.
Read more →SCLXScilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL
Scilex Holding Company presented a post-hoc analysis of the C.L.E.A.R. trial regarding the safety and efficacy of SP-102 for lumbosacral radicular pain at the ASIPP Annual Meeting. The findings suggest significant clinical meaningfulness in SP-102's performance against placebo, supported by robust data on various efficacy endpoints. These results position SP-102 as a potentially safer non-opioid therapeutic option for pain management. The poster presented at the conference will also be published in the Pain Physician journal.
Read more →SCLX▲ +7.6%on this news
Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL.
Scilex Holding Company announced its upcoming presentation of a post-hoc analysis from the C.L.E.A.R. trial at the 27th Annual Meeting of ASIPP, scheduled for May 15-17, 2025, in Orlando, FL. The analysis focuses on the clinical meaningfulness of safety and efficacy for SP-102 in treating lumbosacral radicular pain. This presentation aims to provide insights into SP-102's potential benefits while acknowledging the associated risks and regulatory uncertainties. Attendees can view the poster during the event as well as through the conference app.
Read more →SCLXScilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule
Scilex Holding Company has regained compliance with the NASDAQ minimum bid price requirement, allowing its common stock and public warrants to continue trading on the Nasdaq Capital Market. The company met the requirement by maintaining a closing bid price of at least $1.00 for ten consecutive trading days. Scilex focuses on non-opioid pain management products and is engaged in the development of various therapies, although some risks regarding trial success and market acceptance persist.
Read more →SCLX▼ -15.1%on this news
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025
Scilex Holding Company has announced a change in the record date for its preferred stock dividend from April 11, 2025, to May 2, 2025. This decision was made by the Board of Directors, which retains the right to change the record date further. The payment date is expected to be set within 60 days following the new record date. Scilex focuses on developing non-opioid pain management solutions and has ongoing product candidates aimed at treating various pain-related conditions.
Read more →SCLX▼ -11.6%on this news· ran to -42% by day 3shared move
Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis
Scilex Holding Company announced that the FDA has granted Orphan Drug Designation for colchicine to treat pericarditis. This designation is aimed at rare diseases and follows the approval of Gloperba®, a liquid form of colchicine, which is intended to help patients with difficulties swallowing pills. The approval is a key milestone that could enhance Scilex’s market position and provide valuable treatment options for patients suffering from pericarditis. The company continues to focus on developing solutions for acute and chronic pain management.
Read more →SCLXScilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB ’s Acute Treatment of Migraine With or Without Aura in Canada
Scilex Holding Company has received approval from Health Canada's Pharmaceutical Drugs Directorate for ELYXYB, a ready-to-use oral solution for the acute treatment of migraines with or without aura. This drug, which is the only FDA-approved solution of its kind, aims to address unmet needs in the Canadian market where over 2.7 million individuals suffer from migraines. ELYXYB demonstrated efficacy in clinical studies, providing pain relief in about 50% of patients within 45 minutes. The approval opens significant revenue opportunities, as the migraine therapeutics market in Canada is projected to reach approximately $400 million by 2025.
Read more →SCLX▼ -21.5%on this newsshared move
Scilex Holding Company Announces 1-for-35 Reverse Stock Split
Scilex Holding Company has announced a 1-for-35 reverse stock split of its outstanding shares, effective April 15, 2025. The decision was made following stockholder approval at a special meeting held on March 19, 2025, and aims to help the company comply with Nasdaq’s minimum bid price requirement. Post-split, Scilex will have approximately 6.9 million shares issued and outstanding. The reverse stock split will also adjust the exercise prices for Scilex’s outstanding warrants and other securities accordingly.
Read more →SCLXScilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva
Scilex Holding Company has filed an appeal to the U.S. Court of Appeals for the Federal Circuit, in response to a lower court ruling that found Aveva's proposed product did not infringe Scilex's ZTlido patents. The company is committed to continuing its legal action against Aveva, emphasizing the strength of its intellectual property. Scilex also plans to advance its pipeline of non-opioid pain management products despite the ongoing legal challenges.
Read more →SCLXScilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025
Scilex Holding Company announced a change in the record date for its preferred stock dividend, moving it from January 28, 2025, to April 11, 2025. This decision was made by the Board of Directors and is subject to further changes. The actual payment date will be determined within 60 days following the new record date. Scilex is focused on non-opioid pain management solutions and is pursuing a joint venture with IPMC Company.
Read more →SCLX▼ -6.4%on this news
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025
Scilex Holding Company announced that the U.S. Bankruptcy Court has extended the lock-up period on its Dividend Stock, initially distributed by Sorrento Therapeutics, to April 14, 2025. This decision restricts the sale or transfer of these shares, which might affect liquidity for investors. Scilex continues to focus on developing non-opioid pain management solutions, while also navigating potential challenges related to product development and regulatory approvals.
Read more →SCLXScilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB in Acute Pain Indication
Scilex Holding Company announced that the U.S. FDA has acknowledged the submission of its Supplemental New Drug Application (SNDA) for ELYXYB for the acute pain indication. This acknowledgment positions ELYXYB as a potential first-line therapy for managing acute pain. Scilex is focused on advancing non-opioid treatments to address high unmet needs. However, the approval of the sNDA remains uncertain and poses a risk to the company's plans.
Read more →SCLX▼ -5.8%on this newsshared move
Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)
Scilex Holding Company announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its Quarterly Report for the quarter ended September 30, 2024. This achievement reflects the company's commitment to meeting regulatory requirements and progressing in the biopharma market. Scilex is focused on the development and commercialization of non-opioid pain management products, which are positioned to address significant unmet medical needs. The company is also developing several product candidates targeting various pain indications.
Read more →SCLX▼ -5.8%on this newsshared move
Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025
Scilex Holding Company has announced the extension of the maturity date for its Senior Secured Promissory Note issued to Oramed Pharmaceuticals Inc. from March 21, 2025, to December 31, 2025. This extension is expected to include additional business conduct covenants. Scilex focuses on non-opioid pain management and has a portfolio of products already approved by the FDA. However, the company faces financial risks and uncertainties related to its ongoing clinical developments.
Read more →SCLX▼ -5.8%on this newsshared move
Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC
Scilex Holding Company has announced that its Tranche B senior secured convertible note holders plan to participate in the funding and licensing of Gloperba®'s ex-U.S. commercialization rights from Romeg Therapeutics, LLC. This collaboration will also involve managing the worldwide licensing and distribution of Gloperba® through the establishment of a joint venture. Scilex focuses on developing non-opioid pain management products and aims to target high unmet needs in the pain management market.
Read more →SCLX▼ -5.8%on this newsshared move
Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB in Acute Pain Indication
Scilex Holding Company (SCLX) announced it will file a Supplemental New Drug Application (SNDA) with the FDA for its product ELYXYB® as a treatment for acute pain. ELYXYB®, a new oral liquid formulation of celecoxib, has shown superior analgesic efficacy in clinical trials compared to placebo, particularly after dental surgery. The drug aims to provide a rapid, non-opioid alternative for managing acute pain, addressing a significant market need as many patients are currently reliant on opioids. This filing, if approved, could enhance Scilex's portfolio and position in the pain management sector.
Read more →SCLX▼ -5.8%on this newsshared move
Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024
Scilex Holding Company has filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and expects to regain compliance with Nasdaq Listing Rule 5250(c)(1). The company continues to develop its portfolio of non-opioid pain management products and has notable ongoing clinical developments with its product candidates, including SP-102 and SP-103. Despite this positive outlook, there are several risks associated with regulatory approvals, market acceptance, and the future of its joint venture with IPMC Company.
Read more →SCLX▲ +5.2%on this newsshared move
Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba , an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults
Scilex Holding Company has amended its license agreement with Romeg Therapeutics to gain worldwide rights to commercialize Gloperba, a liquid oral formulation of colchicine approved for preventing painful gout flares in adults. This strategy is aimed at expanding the market reach of Gloperba, which addresses significant patient needs due to its precise dosing capabilities, especially for those unable to swallow pills. Given the rising global incidence of gout, the development and marketing of Gloperba could improve patient outcomes while positioning Scilex favorably in the non-opioid pain management market.
Read more →SCLXScilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido vs. Lidocaine 5% Patch
Scilex Holding Company has announced new retrospective claims data published by Pain Medicine News that highlights the efficacy of ZTlido® over lidocaine 5% patches. The study found that a greater percentage of patients treated with ZTlido® either decreased or discontinued opioid use compared to those on the 5% patch. Additionally, ZTlido was linked to a significant reduction in opioid use with more patients achieving a 20% or greater decrease. Overall, ZTlido is highlighted as an effective option for neuropathic pain management.
Read more →SCLX▲ +8%on this news· ran to +22% by day 3
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025
Scilex Holding Company has announced a change to the record date for its upcoming dividend from November 7, 2024, to January 28, 2025. The decision was made by the company's Board of Directors and the payment date will be determined later, typically within 60 days following the new record date. This adjustment may lead to uncertainty for stakeholders, as the Board retains the right to make further changes to the record date or the dividend itself. Scilex's overall strategy focuses on developing non-opioid pain management solutions and its joint venture with IPMC Company aims to target neurodegenerative and cardiometabolic diseases.
Read more →SCLXScilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
Scilex Holding Company has declared an early installment payment of $13.2 million on its senior secured promissory note to Oramed Pharmaceuticals. This move signals a commitment to financial stability while preparing for future initiatives in treating obesity, neurodegenerative diseases, and pain management. The remaining balance under the note will be settled by March 21, 2025, allowing for complete retirement of the note and positioning Scilex for potential collaborations and product expansions. However, there remain risks associated with the company’s ability to fulfill its financial obligations and the development timeline of its product candidates.
Read more →SCLXScilex Holding Company Announces Closing of $17 Million Registered Direct Offering
Scilex Holding Company has announced the completion of a $17 million registered direct offering, involving the sale of approximately 26.4 million shares of common stock and various warrants. The funds are earmarked for a range of corporate needs, including research and development, commercialization efforts, and potential acquisitions. This offering follows a previously filed registration statement with the SEC, showcasing Scilex's focus on addressing unmet medical needs in pain management and neurodegenerative diseases.
Read more →SCLX▼ -12.7%on this newsshared move
Scilex Holding Company Announces $17 Million Registered Direct Offering
Scilex Holding Company has announced a $17 million registered direct offering of its shares and pre-funded warrants to institutional investors. The offering includes over 26 million shares at a price of $0.59 each and aims to secure funds for various corporate activities, including research, development, and potential acquisitions. The closing of this offering is anticipated to occur by December 13, 2024, subject to customary conditions. The funds raised will help support Scilex's mission to provide innovative pain management solutions and advance its existing product candidates.
Read more →SCLXScilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer’s Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025
Scilex Bio, a controlling interest of Scilex Holding Company, has initiated a Phase 2 clinical trial for KDS2010, a novel oral tablet aimed at treating Alzheimer’s disease. The trial is currently recruiting participants in South Korea, with plans to expand the U.S. patient cohort by 2025. KDS2010, a reversible selective MAO-B inhibitor, is designed to mitigate cognitive decline associated with Alzheimer's by targeting GABA regulation in the brain. Promising pre-clinical studies have indicated its potential to enhance memory and learning.
Read more →SCLX▼ -16.4%on this newsshared move
Scilex Holding Company Enters into a Binding Term Sheet for a Joint Venture with IPMC and Bio Open Innovation Consortium to Develop and Commercialize a Phase 2 Clinical Stage, Potential Best-In-Class Novel Oral Tablet for the Treatment of Obesity and Neurodegenerative Diseases Including Alzheimer’s Disease
Scilex Holding Company has entered a binding term sheet to form a joint venture called Scilex Bio with IPMC and the Bio Open Innovation Consortium to develop the Phase 2 clinical stage oral tablet KDS2010. This compound targets obesity and neurodegenerative diseases, including Alzheimer's, showing favorable results in preclinical studies. With a projected substantial market for obesity treatments and Alzheimer's drugs, Scilex aims to leverage IPMC's innovation to improve treatment outcomes for these conditions. Operations of the joint venture are expected to commence in Q1-2025.
Read more →SCLX▼ -5.6%on this news
Scilex Holding Company Announces Receipt of Notice from Nasdaq
Scilex Holding Company was notified by Nasdaq that it is not in compliance with continued listing requirements due to the late filing of its Q3 Form 10-Q. The company has a 60-day window to submit a plan to regain compliance, potentially extending the deadline for filing further. Scilex aims to file the report as soon as possible but faces significant risks if they do not meet the established deadlines.
Read more →SCLX▼ -10.3%on this news
Scilex Holding Company Announces Presentation of Data at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024
Scilex Holding Company has announced that it will present data at the 2024 American College of Rheumatology Convergence Conference in Washington, D.C., from November 14 to 19, 2024. The presentation will focus on GLOPERBA® (colchicine oral solution), the first liquid formulation that enables precision dosing for patients at risk of gout flares, especially those with renal impairment. An updated FDA label for GLOPERBA® reflects important dosing adjustments, underscoring its significance in pain management for such patients.
Read more →SCLX▼ -5.3%on this news
Scilex Pharmaceuticals Inc, a Wholly Owned Subsidiary of Scilex Holding Company, Announces Successful End of Phase II Meeting with FDA Leading to an Agreed Path Forward to NDA Upon Completion of Phase III Trials for Blockbuster Product Candidate, SP-103 (Lidocaine Topical System) 5.4%, a Next-Generation, Triple-Strength Formulation of ZTlido, for the Treatment of Chronic Neck Pain Associated with Muscle Spasms
Scilex Pharmaceuticals has announced a successful conclusion to its Phase II meeting with the FDA regarding its product candidate SP-103, a lidocaine topical system designed for treating chronic neck pain associated with muscle spasms. This development provides a clear path for Scilex toward filing for New Drug Application (NDA) upon the completion of Phase III trials. Significant market potential has been identified for SP-103, with projected annual sales reaching $1.2 billion by the sixth year post-launch. Scilex also seeks to maximize its value, considering options for a spinoff or public listing of its subsidiary.
Read more →SCLXScilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
Scilex Holding Company has announced a record date of November 7, 2024, for dividends of preferred stock while highlighting concerns about manipulative short selling in its common stock. The management believes over 12 million shares are sold short unlawfully, affecting stockholder voting and rights. The company is urging stockholders to demand the delivery of any Dividend Shares from their brokers and avoid lending their shares to prevent naked short selling. Scilex’s proactive measures suggest a strong commitment to enhancing stockholder value amidst these challenges.
Read more →SCLX▲ +14%on this newsshared move
Scilex Holding Company sets November 7, 2024 as the Record Date for a Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary
Scilex Holding Company has announced a record date of November 7, 2024, for a dividend of 5 million shares of preferred stock to its stockholders. This dividend is linked to the company's business combination with Denali Capital Acquisition Corp, with Semnur Pharmaceuticals valued at $2.5 billion. The product SP-102 could generate annual peak sales of $3.6 billion, enhancing Scilex's position in the non-opioid pain management market. However, the dividend's payment depends on the Board's discretion prior to the set payment date.
Read more →SCLX▲ +7.7%on this news· ran to +21% by day 3
Scilex Holding Company Announces that its Board of Directors has Authorized Management to Explore Ways to Maximize the Value of its Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., including by way of conducting a spinoff or public listing of securities of Scilex Pharmaceuticals Inc. Scilex Pharmaceuticals Commercial Products Include Three Non-Opioid Approved Products and Pipeline of Phase 3 Ready SP-103 With Greater Than a $1.0 Billion Revenue Potential
Scilex Holding Company has authorized management to explore options to maximize the value of its subsidiary, Scilex Pharmaceuticals, potentially through a spinoff or public listing. The parent company believes that the value of Scilex Pharma may exceed its current valuation. Scilex's commercial offerings, including the pain relief product ZTlido and the migraine treatment ELYXYB, are showing positive sales trends. Additionally, the future product SP-103 has a strong projected sales potential, further enhancing the company's outlook.
Read more →SCLX▼ -8.3%on this news
Scilex Holding Company Announces Closing of a $50 Million Registered Convertible Financing
Scilex Holding Company has successfully closed a $50 million registered direct offering of senior secured convertible notes. The proceeds are aimed at repaying a portion of existing debt and supporting general corporate activities. The notes carry a 5.5% annual interest rate and are convertible into common stock at a set price. This financing event signals investor confidence but also poses financial risks associated with debt obligations and the uncertain regulatory landscape for Scilex's product pipeline.
Read more →SCLX▼ -8.3%on this news
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Quarter Ended September 30, 2024
Scilex Holding Company has reported preliminary unaudited financial results for the quarter ending September 30, 2024. ZTlido net sales are projected to be between $11.0 million and $13.0 million, reflecting a year-over-year growth of 9% to 29%. Total product net sales are estimated to range from $12.0 million to $14.0 million, showing a growth of 19% to 39%. However, the company cautions that these results are subject to change pending further review and audit.
Read more →SCLX▼ -6.6%on this news· ran to -20% by day 3shared move
Scilex Holding Company Announces Signing of a $50 Million Registered Convertible Financing to Refinance and Restructure Existing Debt & Further Strengthens Financial Profile
Scilex Holding Company has announced a definitive agreement for a $50 million registered convertible financing aimed at refinancing and restructuring existing debt. The move is expected to bolster its financial profile and support its multi-year transformation into a leading non-opioid pain management company. This refinancing follows significant actions taken by Scilex over the past year to reduce its debt load by over $80 million. The closing of the offering is anticipated on or around October 7, 2024.
Read more →SCLX▲ +12.5%on this news
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to January 31, 2025
Scilex Holding Company announced that the U.S. Bankruptcy Court has extended the lock-up period on the Scilex Dividend Stock until January 31, 2025. This decision affects shares that were previously distributed by Sorrento Therapeutics to its stockholders as a dividend. The lock-up will prevent any sale or transfer of these shares during this extended period. This announcement indicates ongoing legal proceedings concerning Sorrento’s distribution of the Dividend Stock and the potential claims associated with it.
Read more →SCLXScilex Holding Company Announces the Continuing Support from Endeavor Distribution LLC in the Multi-Year Agreement for Scilex’s Commercial Products and the Satisfaction of FSF 33433 LLC $10 Million Loan
Scilex Holding Company has announced a continuing partnership with Endeavor Distribution LLC to enhance the distribution of its non-opioid pain management products. This collaboration will aid in distributing the ZTlido product to various healthcare services across the U.S., expanding access to patients with acute and chronic pain. Additionally, the company has satisfied a $10 million loan obligation through product deliveries. Scilex projects significant orders, enhancing its market presence and addressing unmet needs in pain management.
Read more →SCLXScilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy (NABP )
Scilex Holding Company has announced it has received Drug Distributor Accreditation from the National Association of Boards of Pharmacy (NABP). This recognition affirms that Scilex has met all criteria for drug distribution, enhancing its credibility within the pharmaceutical industry. The accreditation is expected to support Scilex's efforts in commercializing its non-opioid pain management products, positioning the company favorably for future growth. Scilex's focus on innovative solutions for pain relief highlights its commitment to addressing unmet medical needs.
Read more →SCLXScilex Holding Company to Present at the 26th Annual H.C. Wainwright Global Investment Conference
Scilex Holding Company (Nasdaq: SCLX) announced its participation in the 26th Annual H.C. Wainwright Global Investment Conference, which will be held from September 9-11, 2024, in New York City. Jaisim Shah, the CEO and President, is scheduled to present the company's strategic vision and product developments. Scilex is focused on non-opioid pain management therapies, highlighting its ongoing commitment to addressing unmet medical needs in pain treatment.
Read more →SCLXScilex Holding Company Announces Acceptance of Presentation at the 2024 American College of Rheumatology Convergence Conference to be held at the Walter E. Washington Convention Center in Washington, D.C. on November 14 – 19, 2024
Scilex Holding Company has announced the acceptance of a presentation at the upcoming 2024 American College of Rheumatology Convergence conference. The presentation will focus on dosing adjustments for GLOPERBA, an innovative oral solution for managing gout flare prophylaxis, particularly in patients with renal impairment. This highlights Scilex's commitment to addressing high unmet needs in acute and chronic pain management through non-opioid therapies. The conference will take place in Washington, D.C., from November 14 to 19, 2024.
Read more →SCLXScilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024
Scilex Holding Company announced that it will present oral, poster presentations, and symposia on its product ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas from September 3-5. Key topics include strategies to optimize pain management and analyses showing decreased opioid use and costs with ZTlido compared to alternatives. The involvement of prominent experts in pain management highlights the significance of these findings in addressing unmet needs in chronic pain treatment.
Read more →SCLXScilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA Label
Scilex Holding Company has received FDA approval for GLOPERBA®, a liquid oral formulation of colchicine for the prophylaxis of gout flares in adults. GLOPERBA® is designed to offer precision dosing for the over 70% of gout patients who have comorbid conditions that affect dosing regimens. This innovative formulation is expected to improve outcomes for patients susceptible to gastrointestinal side effects from traditional colchicine tablets. The gout treatment market is anticipated to grow significantly, indicating a strong potential demand for GLOPERBA® among healthcare providers and patients.
Read more →SCLXScilex Holding Company Announces the U.S. Patent and Trademark Office Will Be Issuing New ELYXYB Patent Related to the Treatment of Acute Pain
Scilex Holding Company announced that the U.S. Patent and Trademark Office will issue a new patent related to the treatment of acute pain, focusing on its acute migraine treatment drug, ELYXYB. This development, expected in late 2024, enhances Scilex's intellectual property portfolio. ELYXYB is recognized as a leading non-opioid therapy for migraines with demonstrated rapid effectiveness in providing pain relief. The patent covers methods of treating acute pain, indicating further potential applications for the product.
Read more →SCLXScilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa
Scilex Holding Company has entered into a Master Distributor Agreement with Devart Middle East and CH Trading Group for the distribution of its pain management product ZTlido in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa. This agreement builds on a previous product distribution agreement and aims to enhance ZTlido's commercialization across several Middle Eastern and North African territories. ZTlido, a lidocaine topical system, is designed for neuropathic pain relief and has already established a strong market presence in the U.S., where it is the top prescribed non-opioid pain medication.
Read more →SCLX▼ -5.7%on this news
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024
Scilex Holding Company has announced preliminary unaudited financial results for July 2024, revealing substantial growth in ZTlido net sales, estimated between $4.0 million and $5.0 million, compared to $2.7 million in July 2023. Total product net sales for the month are projected to be between $4.3 million and $5.3 million, showing an increase of 54% to 89% from the previous year. These results indicate a strong performance and positive outlook as the company continues to focus on non-opioid pain management solutions. However, Scilex emphasizes that these figures are preliminary and subject to change as the independent auditor has not reviewed them.
Read more →SCLXScilex Holding Company Announces Publication of Its Inaugural Sustainability Report
Scilex Holding Company has released its first sustainability report, outlining its efforts towards environmental stewardship, development excellence, and social responsibility. The report highlights Scilex's commitment to reducing its environmental footprint while improving patient access to non-opioid pain management products. Additionally, it emphasizes the company's dedication to an inclusive workforce and transparent corporate governance. CEO Jaisim Shah stated that this report reflects their ongoing commitment to corporate responsibility and positive change.
Read more →SCLXScilex Holding Company Strengthens Board of Directors with Appointment of Highly Accomplished Leader in Interventional and Multidisciplinary Spine, Musculoskeletal and Orthopedic Care, Annu Navani, M.D.
Scilex Holding Company has appointed Dr. Annu Navani to its Board of Directors, who brings a wealth of experience in interventional spine and pain management. Dr. Navani, the former CEO of Comprehensive Spine and Sports Center, has transitioned to her role at Scilex as the company seeks to advance its non-opioid pain management products. Scilex's CEO expressed confidence that Dr. Navani's expertise will enhance the company's progress in delivering innovative pain therapies. The addition aligns with Scilex's ongoing growth and commitment to improving patient outcomes in pain management.
Read more →SCLXScilex Holding Company Announces Collaboration to Leverage ACEA Therapeutics’ R&D Expertise and Local Market Connections to Support the Expansion of ZTlido Program in ex-US and Potentially Provide Additional Access to Patients in Certain Key Markets in Far East Region
Scilex Holding Company has announced a collaboration agreement with ACEA Therapeutics to promote its non-opioid pain management product ZTlido in Greater China. Under this partnership, ACEA will be the exclusive distributor in the region and will initiate the commercialization process once ZTlido is approved locally. The MOU also includes potential rights for future formulations of the product. This strategic move aims to address significant pain management needs in a rapidly growing market.
Read more →SCLXScilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York
Scilex Holding Company (SCLX) announced it will ring the Nasdaq Closing Bell on July 5, 2024, to celebrate the launch of GLOPERBA®, the first oral liquid medicine for the prevention of painful gout flares. This highlights Scilex's commitment to developing innovative non-opioid solutions for pain management. The event will involve key executives from the company, showcasing their achievements in bringing new pain management products to market. Scilex has developed a portfolio of non-opioid products and has a promising pipeline of candidates advancing through clinical trials.
Read more →SCLXScilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended June 30, 2024 and Second Quarter of 2024
Scilex Holding Company has reported preliminary unaudited financial results for June 2024 and the second quarter of 2024, highlighting significant growth in net sales for ZTlido® and total product revenues. ZTlido® net sales saw an increase of 70% to 104% year-over-year for June, while total product sales rose by 77% to 116%. However, the company also experienced a notable decrease in cash reserves and reported a net loss, although this was less than the previous year. Scilex remains optimistic about its sales trends for ELYXYB® and Gloperba® as it continues to expand its market presence.
Read more →SCLX▲ +7.1%on this news· ran to -19% by day 3
Scilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.
Scilex Holding Company has announced a non-exclusive distribution agreement with Endeavor Distribution LLC, a respected distributor with expertise in logistics. This partnership aims to enhance the commercialization and distribution of Scilex's non-opioid pain management products. The CEO of Scilex expressed optimism about the accelerated growth of their product lineup, which includes the successful launch of three non-opioid products. This agreement marks a strategic effort to expand their market reach and better serve specialized customers.
Read more →SCLX▲ +8.1%on this news· ran to +44% by day 1shared move
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
Scilex Holding Company announced the publication of Phase 3 trial results for SP-102 (SEMDEXA™) in the PAIN Journal, confirming the treatment's efficacy for lumbosacral radicular pain (sciatica). The study met its primary and key secondary endpoints, showing a significant reduction in pain intensity for over a month and improvement in disability scores. The trial involved a large sample of subjects and demonstrated a favorable safety profile with no serious adverse events reported. SP-102 is positioned to become the first FDA-approved corticosteroid for epidural injection, addressing unmet medical needs in pain management.
Read more →SCLXScilex Holding Company to Present Poster on ELYXYB (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society (AHS) to be Held in San Diego, CA on June 13-16, 2024
Scilex Holding Company will present a poster on its product ELYXYB (celecoxib oral solution) at the 66th Annual Scientific Meeting of the American Headache Society in June 2024. The presentation will focus on results from a post-hoc analysis of two Phase 3 clinical trials showing that ELYXYB provided significantly better outcomes than placebo for patients who did not respond to triptans. Notably, 33.3% of patients treated with ELYXYB achieved pain freedom after 2 hours, compared to 14.3% for placebo. This research underscores ELYXYB's potential as an effective acute treatment for migraine.
Read more →SCLX▲ +18.7%on this news· ran to +44% by day 3shared move
Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies
Scilex Holding Company has announced a $100 million financing deal with Perigrove LLC and Graf Holdings, aimed at repaying existing debt and supporting general corporate purposes. The deal includes royalty-based payments and warrants for common stock. Management expresses optimism about the company’s revenue prospects, anticipating over $1 billion in revenues from a growing product pipeline within the next 4-5 years. The financing is expected to improve cash flow and reduce reliance on outside capital.
Read more →SCLX▲ +18.7%on this news· ran to +44% by day 3shared move
Scilex Holding Company Announces That Many National Pharmacy Chains and Independent Pharmacies Have Begun Stocking GLOPERBA
Scilex Holding Company recently launched its new product, GLOPERBA, an FDA-approved oral liquid treatment for the prophylaxis of gout flares. The product has been shipped to several national pharmacy chains and independent pharmacies, marking a significant step in its distribution. GLOPERBA is positioned to meet the needs of an estimated 9.2 million people in the U.S. suffering from gout, with the gout treatment market expected to reach $2.0 billion by 2028. Scilex is also exploring stocking arrangements with additional pharmacy chains to expand access to the product.
Read more →SCLXScilex Holding Company Announces Stocking of GLOPERBA is Underway in all of the Wholesalers with which Scilex has Stocking Arrangements Throughout the U.S.
Scilex Holding Company (SCLX) has announced that stocking of its new product, GLOPERBA®, is currently underway across all wholesalers in the U.S. GLOPERBA® is the first liquid oral formulation of colchicine, aiming to provide an effective prophylactic treatment for adults suffering from painful gout flares. The company expects this stocking process to be completed by June 12, 2024, and is offering a co-pay savings card to support patients. This launch marks Scilex's third commercial product as it continues to focus on non-opioid pain management solutions.
Read more →SCLX▲ +9.3%on this news· ran to +23% by day 3shared move
Scilex Holding Company announces the U.S. FDA has approved the sNDA for commercial manufacturing of Gloperba which will be launched in the US in the week of June 10th 2024
Scilex Holding Company has received FDA approval for the commercial manufacturing of Gloperba, a liquid formulation of colchicine, intended for the prophylaxis of gout flares in adults. Set to launch in the U.S. on June 10, 2024, Gloperba aims to address the needs of gout patients who require precise dosing to avoid severe side effects. The company expects this product to augment its non-opioid pain management portfolio and target a growing market amid increasing gout cases. Scilex will distribute Gloperba through its established network of wholesalers and pharmacies.
Read more →SCLXScilex Holding Company Sends Letters to the U.S. Securities and Exchange Commission and Financial Industry Regulatory Authority Regarding Illegal Market Manipulation of the Common Stock of Scilex Holding Company
Scilex Holding Company has sent letters to the U.S. Securities and Exchange Commission and the Financial Industry Regulatory Authority regarding alleged illegal market manipulation of its common stock. The company aims to combat issues related to 'naked short' selling, which it asserts harms shareholder value. By taking this action, Scilex seeks to safeguard the rights of its investors and address potential violations of SEC regulations. The situation underscores ongoing challenges in maintaining market integrity.
Read more →SCLXScilex Holding Company Announces it has been Added to the MSCI Global Microcap Index
Scilex Holding Company has announced its inclusion in the MSCI Global Micro Cap Index, effective after market close on May 31, 2024. This recognition follows a strong first quarter for Scilex, where there was notable interest in its portfolio of non-opioid pain management products. CEO Jaisim Shah expressed optimism about the company's progress and the acknowledgment by the MSCI index. However, the company also acknowledged potential risks such as stock price volatility and regulatory challenges for its product candidates.
Read more →SCLXScilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company
Scilex Holding Company has sent a letter to the U.S. House of Representatives addressing concerns related to illegal market manipulation of its common stock. The company cites practices like 'naked short' selling that violate SEC regulations and aim to protect shareholder rights. Scilex emphasizes its commitment to combat these manipulative tactics while continuing to innovate in non-opioid pain management products. The letter reflects the company's proactive stance in response to market challenges and aims to garner support from legislative leaders.
Read more →SCLXScilex Holding Company Announces Final Court Approval of a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s intent to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba
Scilex Holding Company has received final court approval for a settlement agreement with Takeda Pharmaceuticals, resolving a patent infringement lawsuit related to its liquid colchicine product, Gloperba. This agreement allows Scilex to pursue an expansion of Gloperba's label after it submitted a Consent Judgment to the FDA. The new label is expected to provide flexibility in dosing, addressing specific medical needs while enhancing treatment adherence. The company aims to launch the expanded version in the first half of 2024.
Read more →SCLX▲ +8%on this newsshared move
Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
Scilex Holding Company has announced steps to protect its stockholders from manipulative and naked short selling practices affecting their common stock. Management noted that a significant number of shares are being sold short, along with unfulfilled Dividend Shares distributed earlier. The company is encouraging stockholders to take actions against such practices while providing guidance and resources to help them do so. This situation highlights ongoing concerns about stockholder rights and market integrity.
Read more →SCLXScilex Holding Company Announces Closing of $15 Million Registered Direct Offering
Scilex Holding Company announced the successful closing of a $15 million registered direct offering of its common stock and accompanying warrants. The offering, which includes 15 million shares at a purchase price of $1.00 each, will provide funding for working capital and general corporate purposes. This initiative supports Scilex's focus on developing and commercializing non-opioid pain management products for acute and chronic pain. The company aims to enhance its product pipeline, which includes existing FDA-approved products and several candidates in development.
Read more →SCLX▼ -13%on this newsshared move
Scilex Holding Company Announces $15 Million Registered Direct Offering
Scilex Holding Company has announced a $15 million registered direct offering, securing investment through the sale of shares and warrants. The company plans to use the proceeds for working capital, R&D, and general corporate purposes. This funding comes as Scilex aims to enhance its non-opioid pain management portfolio, which includes existing products and promising candidates currently in various stages of development. The completion of the offering is anticipated to occur shortly, contingent on the usual closing conditions.
Read more →SCLX▼ -9.4%on this news· ran to -30% by day 3
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses
Scilex Holding Company announced preliminary unaudited financial results for ZTlido® for Q1 2024, indicating growth in gross and net sales compared to Q1 2023. Plans to launch Gloperba® in the first half of 2024 have been outlined, aiming to expand their non-opioid product offerings. The company intends to reduce research and administrative expenses to focus on enhancing commercial activities. However, the results are preliminary and lack full audit verification, introducing some uncertainty regarding actual performance.
Read more →SCLXScilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
Scilex Holding Company has announced the launch of co-pay programs for its products ZTlido and ELYXYB, capping monthly out-of-pocket costs for insured patients at $25. The addition of ELYXYB to a multi-state Medicaid pharmaceutical purchasing group aims to enhance its accessibility across several states. These initiatives are part of Scilex’s efforts to improve patient affordability in non-opioid pain management. The company emphasizes its commitment to providing effective treatments for patients suffering from acute and chronic pain.
Read more →SCLX▲ +6.6%on this news
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
Scilex Holding Company announced an extension of the lock-up period for shares of Scilex stock that were distributed as a dividend by its former parent, Sorrento Therapeutics. The U.S. Bankruptcy Court extended the restrictions on these shares until the end of September 2024 or possibly sooner, depending on the legal proceedings surrounding the dividend distribution. This extension prohibits holders of the Dividend Stock from selling or transferring their shares until the lock-up is lifted.
Read more →SCLXScilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
Scilex Holding Company has announced that out-of-pocket expenses for its products, including ZTlido, ELYXYB, and the upcoming Gloperba, will be capped at $25 per month for commercially insured patients, with some eligible patients potentially paying nothing. This initiative aims to improve patient access to non-opioid pain management therapies. Additionally, Scilex has resolved recent disruptions in co-pay savings card processing due to a cyber-attack on a partner company. The company continues to advance its product portfolio while facing potential uncertainties in clinical development and market acceptance of its pipeline therapies.
Read more →SCLXScilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba
Scilex Holding Company has announced a Settlement Agreement with Takeda Pharmaceuticals to resolve a Paragraph IV patent infringement lawsuit related to its product Gloperba, which is a liquid colchicine treatment for gout. This agreement includes a non-exclusive license to certain Takeda patents, allowing Scilex to continue its efforts to expand Gloperba's label. The settlement is subject to court and regulatory approvals. Scilex is poised to launch Gloperba in the first half of 2024, representing a significant step forward in its product development pipeline.
Read more →SCLXScilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed
Scilex Holding Company announced its intention to seek FDA approval for modifying the Gloperba label to allow specific dosing guidance for patients with renal impairment. This modification will provide a starting dose of 0.3 mg/day for those with severe renal impairment and help address the unmet medical needs in gout treatment. Gloperba, the first liquid oral version of colchicine, aims to improve precision dosing for patients affected by gout, particularly those also suffering from gastrointestinal issues. The company expects to launch Gloperba in the first half of 2024.
Read more →SCLXScilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
Scilex Holding Company (SCLX) has announced the full repayment of approximately $1.3 million under convertible debentures and an early payment of $15 million on a senior secured promissory note. This financial maneuver is aimed at positioning the company for future growth in innovative, non-opioid pain management solutions. CEO Jaisim Shah emphasized the importance of these developments in expanding commercialization efforts and pursuing new collaborations to address the opioid crisis.
Read more →SCLXScilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB for Acute Treatment of Migraine With or Without Aura in Canada
Scilex Holding Company has responded to questions regarding the composition of their ELYXYB patent, which is currently under review for new drug submission by Health Canada. ELYXYB, an oral solution for the acute treatment of migraines, is anticipated to be a promising option given the significant market size in Canada. The company expects the review process to take approximately 12 months, and clinical studies have shown that ELYXYB can offer rapid pain relief to patients. This development highlights Scilex's focus on providing effective non-opioid pain management solutions.
Read more →SCLXScilex Holding Announces Issuance of Halal Certification for its ZTlido product by Circle H International, Inc.
Scilex Holding Company has announced the Halal certification of its product ZTlido, issued by Circle H International, which allows for its marketing in Islamic markets worldwide. This certification is seen as a significant milestone in Scilex's strategy to expand into the Middle East and North Africa, with an initial focus on the UAE and Saudi Arabia. The Halal certification signifies compliance with Islamic standards and is expected to facilitate Scilex's growth in international markets, particularly given the sizeable Muslim population globally. Scilex's focus on non-opioid pain management solutions aligns with growing demand in these markets.
Read more →SCLXScilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement
Scilex Holding Company's subsidiary, Scilex Pharmaceuticals Inc., has entered into a Definitive Settlement Agreement with Virpax Pharmaceuticals, Inc., approved by the U.S. Bankruptcy Court. This agreement includes an initial payment of $3.5 million and a subsequent payment of $2.5 million, along with potential royalty payments based on sales of specific drug candidates. The settlement aims to release claims related to ongoing litigation while allowing Scilex to move forward in its operations. However, litigation against former president Anthony Mack continues.
Read more →SCLXScilex Holding Company Announces Closing of $10 Million Bought Deal Offering
Scilex Holding Company announced the successful closing of a public offering generating $10 million in gross proceeds. The offering included 5,882,353 shares of common stock and warrants, priced at $1.70 each. The company plans to utilize the proceeds for working capital and various corporate activities, including research and development, commercialization, and clinical trial expenses. Scilex is focused on advancing its non-opioid pain management therapies while also preparing for potential new product launches in 2024.
Read more →SCLXScilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba , its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024
Scilex Holding Company has announced the upcoming launch of Gloperba, a liquid oral version of colchicine for gout prophylaxis, set at a price of $595 per 150ml bottle. This innovative product, expected to launch in the first half of 2024, aims to address the needs of patients requiring personalized dosing. Scilex's established distribution network and the projected growth of the gout treatment market strengthen its position for this launch. Gloperba is designed specifically to mitigate the risks of colchicine toxicity in patients with comorbid conditions.
Read more →SCLXScilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates
Scilex Holding Company has launched a redesigned website aimed at showcasing its expanding portfolio of non-opioid pain management products. The website features modern design elements, detailed information on the company's therapeutic offerings, and accessible resources for investors and healthcare professionals. CEO Jaisim Shah highlighted the website as a reflection of the company's growth and its mission to provide alternatives to opioid treatments. Additionally, the site includes links to scientific publications and job opportunities, positioning Scilex as an innovative player in pain management.
Read more →SCLXScilex Holding Company Announces that the Official Committee of Unsecured Creditors of Sorrento Therapeutics, Inc., has Filed a Motion with the U.S. Bankruptcy Court to Extend the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend from March 31, 2024 to September 30, 2024
Scilex Holding Company announced that the Official Committee of Unsecured Creditors of Sorrento Therapeutics has filed a motion to extend the lockup period for Scilex shares distributed as a dividend from March 31, 2024, to September 30, 2024. If granted, this would prevent shareholders from selling or transferring their Dividend Stock during this period. The decision is subject to the U.S. Bankruptcy Court's approval, which will be communicated upon ruling.
Read more →SCLX▼ -6.2%on this news· ran to -46% by day 3shared move
Scilex Holding Company Announces $10 Million Bought Deal Offering
Scilex Holding Company announced a $10 million bought deal offering of common stock and accompanying warrants, facilitated by underwriters Rodman & Renshaw and StockBlock Securities. The offering is expected to close around March 5, 2024, pending customary conditions. Proceeds are designated for working capital, commercialization, R&D, and other corporate expenses. Scilex aims to advance its pipeline of non-opioid pain management products, despite uncertainties surrounding market acceptance and regulatory approvals.
Read more →SCLXScilex Holding Company Announces Major Initiative with a Leading National Pharmacy Chain to Stock GLOPERBA in Most of Their Stores Throughout the U.S.
Scilex Holding Company has announced a collaboration with a major national pharmacy chain to stock its gout treatment product, GLOPERBA, in most of their U.S. stores starting in 2024. GLOPERBA is a unique liquid oral version of colchicine approved for the prophylaxis of painful gout flares in adults, addressing a significant market need as cases of gout rise. The company is also exploring partnerships with additional pharmacy chains and has increased production to meet anticipated demand for the product.
Read more →SCLX▲ +11.6%on this news· ran to -36% by day 3shared move
Scilex Holding Company Announces Acceptance of Abstract for Poster and Oral Presentation at the Annual Meeting of the American Academy of Pain Medicine (AAPM)
Scilex Holding Company announced the acceptance of an abstract for a poster and oral presentation at the 2024 Annual Meeting of the American Academy of Pain Medicine, scheduled for March 7-10, 2024. The study compares the effectiveness of ZTlido® (lidocaine topical system 1.8%) with a generic lidocaine 5% patch in reducing opioid utilization among patients with neuropathic pain. Results suggest that ZTlido® provides a greater opioid-sparing effect, indicating its potential for improved pain management. The presentation will highlight the innovative design and performance advantages of ZTlido® in clinical settings.
Read more →SCLX▲ +18.3%on this news· ran to +32% by day 1shared move
Scilex Holding Company Announces that ZTlido Achieves a Major Milestone - Over One Million Patients Treated Since its Launch - and Two Additional Milestones Met
Scilex Holding Company announced significant milestones for its pain management product ZTlido, with over one million patients treated since its launch in October 2018. The product has also become the leading non-opioid branded medication prescribed by pain specialists in the United States. A recent survey indicated that 89% of patients were satisfied with their treatment. The company aims to launch additional non-opioid products in the near future, while acknowledging the risks associated with new product development and market acceptance.
Read more →SCLX▲ +18.3%on this news· ran to +32% by day 1shared move
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Enters into a Term Sheet with Virpax Pharmaceuticals, Inc. Regarding a Mutual Release and Settlement Agreement
Scilex Holding Company's subsidiary, Scilex Pharmaceuticals Inc., has entered into a term sheet with Virpax Pharmaceuticals for a mutual release and settlement agreement. The settlement is expected to include a total of $6 million in payments over the next several months, as well as future royalties tied to the sales of specific drug candidates. While this agreement is a positive step toward resolving ongoing disputes, litigation against former President Anthony Mack is still pending. The parties aim to finalize the definitive settlement agreement by March 1, 2024.
Read more →SCLXScilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido for the Treatment of Chronic Neck Pain
Scilex Holding Company announced the publication of a study in the Anesthesiology Journal that evaluated the use of ZTlido for chronic neck pain. The study showed a positive trend in pain reduction, with 27.7% of patients reporting improvement compared to 14.9% on placebo. While the study's crossover design posed analytical challenges, it provides critical insights for a potential Phase 3 trial of SP-103, a stronger formulation of ZTlido. The results suggest a promising avenue for treating a condition with significant unmet medical need.
Read more →SCLXScilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024
Scilex Holding Company has reported significant accomplishments in 2023, including impressive sales growth for its non-opioid pain management product, ZTlido®, along with successful market entry for ELYXYB®. The company has also strengthened its patent portfolio, ensuring a competitive edge in the sector. Looking ahead to 2024, Scilex aims to launch Gloperba®, targeting the growing U.S. gout market, and further develop its pipeline of innovative pain management solutions. The CEO expresses confidence in the company's strategic direction and commitment to addressing unmet medical needs.
Read more →SCLXScilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information
Scilex Holding Company announced preliminary unaudited financial results for the fiscal year ending December 31, 2023, indicating substantial growth in sales for its products. ZTlido gross sales were estimated between $145 million and $150 million, marking a growth of approximately 51% to 56% year-over-year. The total product net sales also showed an improvement, up to approximately 22% to 38% from the previous year. However, the company has noted that these figures are subject to change as they have not been finalized or reviewed by independent auditors.
Read more →SCLX▲ +15.7%on this news· ran to +46% by day 3
Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB for Acute Treatment of Migraine With or Without Aura in Canada
Scilex Holding Company has submitted a New Drug Submission to Health Canada for ELYXYB, an FDA-approved oral solution for acute migraine treatment. The submission aims to address the needs of over 2.7 million Canadians suffering from migraines, with the Canadian market for migraine therapeutics projected to reach $400 million by 2025. Clinical studies indicate ELYXYB offers rapid pain relief, making it a viable option for patients who do not respond to traditional therapies. Approval from Health Canada is expected within approximately 12 months, pending review cycles.
Read more →SCLX▼ -7.1%on this newsshared move
Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists
Scilex Holding Company announced that their product, ZTlido, has become the most prescribed non-opioid branded pain treatment as of October 2023, according to Symphony Health's prescription data. The market share for ZTlido has risen to 14.2%, up from 11.8% a year ago. Additionally, the company reported significant growth in gross sales, ranging from $125 million to $135 million year-to-date through November 2023, representing a substantial increase compared to $84.6 million during the same period in 2022. Full-year estimates for 2023 suggest potential gross sales could reach between $140 million to $150 million, showing a year-over-year growth rate of approximately 46% to 56%.
Read more →SCLX▲ +11.1%on this newsshared move
Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba as a Liquid Colchicine Formulation Designed for Precision Dosing
Scilex Holding Company announced positive results from market research indicating strong interest among rheumatologists in Gloperba®, its liquid colchicine formulation for gout prophylaxis. The study highlights the potential for Gloperba® to meet the dosing needs of gout patients, particularly those requiring precision to avoid side effects. With the gout treatment market projected to grow significantly, Scilex is positioned to capitalize on this demand. The company is also in discussions with the FDA regarding dosing recommendations for at-risk patient populations.
Read more →SCLX▲ +8.6%on this newsshared move
Scilex Holding Company announces major pharmacy initiative with the national leading pharmacy chain to stock ELYXYB in most of their stores throughout the U.S.
Scilex Holding Company has announced that a leading national pharmacy chain will stock its migraine treatment ELYXYB® in most of their U.S. stores. This follows a previous initiative with another pharmacy chain to stock the product. ELYXYB® is the first ready-to-use oral solution for acute migraine relief, showing significant efficacy in clinical studies. Scilex is also negotiating similar stocking agreements with additional pharmacy chains across the country to enhance product availability.
Read more →SCLXScilex Holding Company Announces Expanded Access to ELYXYB By the Execution of First ELYXYB Insurance Coverage Agreement with One of the Top Three National PBMs (Pharmacy Benefit Manager) for its Medicare Population
Scilex Holding Company has signed an insurance coverage agreement for its ELYXYB product with a major pharmacy benefit manager, enhancing access for Medicare patients. The medication is the only FDA-approved ready-to-use oral solution for the acute treatment of migraines. Recent market studies indicate clinicians' demand for safe alternatives to traditional treatments. The company continues to prioritize patient access and expansion of its portfolio of non-opioid pain management products.
Read more →SCLXScilex Holding Company announces that ZTlido (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State
Scilex Holding Company announced that its product ZTlido will be included as a preferred agent in the Medicaid Preferred Drug List for one Midwestern and one Southern state, effective January 1, 2024. This addition aims to improve accessibility for ZTlido among eligible Medicaid patients in these regions, potentially impacting around 5 million lives covered under Medicaid. Scilex continues its mission of providing innovative non-opioid pain management solutions and is well-positioned for future growth in the market.
Read more →SCLXScilex Holding Company announces the addition of ZTlido (lidocaine topical system) as a preferred agent to the Medicaid Preferred Drug List (PDL) of the State of Tennessee
Scilex Holding Company announced that ZTlido (lidocaine topical system) has been added to the Medicaid Preferred Drug List in Tennessee, effective October 1, 2023. This strategic move is expected to improve access to ZTlido for around 1.5 million eligible adults aged 19 to 64. The company aims to expand the reach of ZTlido and other non-opioid pain management solutions. Scilex is committed to becoming a leader in the pain management sector with a diverse product portfolio.
Read more →SCLX▲ +8%on this newsshared move
Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended November 2023, And Year-To-Date Through November 30, 2023, Based On Currently Available Information
Scilex Holding Company has announced its preliminary unaudited financial results for November 2023, showing robust growth in both gross and net sales. Gross sales for November are estimated between $14.0 million and $15.0 million, with significant year-to-date increases of approximately 48% to 60% compared to 2022. The company projects full year gross sales for ZTlido in 2023 to reach between $140.0 million to $150.0 million, demonstrating strong performance in a competitive market. This announcement underscores Scilex's commitment to expanding its portfolio of non-opioid pain management products.
Read more →SCLX▼ -10.7%on this newsshared move
Scilex Holding Company announces successful FDA audit of enhanced ZTlido manufacturing facility in Japan
Scilex Holding Company has successfully completed an FDA audit of its enhanced ZTlido manufacturing facility in Japan, which will increase production capacity to meet rising demand. The audit confirms compliance with Good Manufacturing Practices, vital for scaling commercial production. In addition, Scilex has secured two new patents covering ZTlido, extending its proprietary protection through January 2031. This progress highlights Scilex's ongoing commitment to advancing non-opioid pain management solutions.
Read more →SCLX▼ -6.2%on this newsshared move
Scilex Holding Company announces pharmacy initiative to stock ELYXYB in over 500 stores for a leading pharmacy chain in the U.S.
Scilex Holding Company has announced a significant agreement to stock its migraine treatment, ELYXYB, in over 500 locations of a leading pharmacy chain in the U.S. This initiative aims to address unmet needs for patients with acute migraines who have limited options. ELYXYB has demonstrated rapid pain relief in clinical studies, with the company also exploring additional stocking arrangements with other chains. However, risks associated with market unpredictability and clinical development hurdles remain.
Read more →SCLX▲ +13.4%on this newsshared move
Scilex Holding Company announces completion of commercial manufacturing of Gloperba with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024
Scilex Holding Company has announced the successful completion of commercial manufacturing for Gloperba®, the first oral liquid version of colchicine for gout flare prophylaxis. The company plans to launch the product in the U.S. in the first quarter of 2024, addressing a significant unmet need in the growing gout treatment market. Scilex's existing distribution network and commercial expertise will facilitate its entry into the market, complementing its other FDA-approved products. The positive market outlook for gout treatments underscores the strategic importance of this launch for Scilex.
Read more →SCLX▲ +6.6%on this news· ran to +42% by day 3shared move
Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB with Potential Advantages Compared to Calcitonin Gene-Related Peptide (CGRP) Products and Triptan Therapy
Scilex Holding Company has announced promising results from a market research study demonstrating significant unmet needs among neurologists and headache specialists for effective solutions in treating acute migraines. The study revealed that 93% of clinicians are seeking alternatives to triptan therapy, highlighting a potential market for Elyxyb, which has shown to provide pain relief in as little as 15 minutes. Moreover, Elyxyb's profile suggests it could outperform existing CGRP products, presenting a favorable option for those with contraindications to triptans. Scilex remains focused on expanding its pipeline of non-opioid pain management therapies to respond to this need.
Read more →SCLX▼ -13.9%on this news· ran to +31% by day 3shared move
Scilex Holding Company Announces Production Increase, Product Availability, and The Brand Marketed and Distributed Under Scilex Pharmaceuticals, Inc. for ELYXYB
Scilex Holding Company announced a significant increase in production of ELYXYB, an FDA-approved oral solution for migraine treatment, to address growing demand. The first commercial batch of ELYXYB has been produced, allowing for enhanced availability in the market. ELYXYB has shown effectiveness in rapid pain relief in clinical trials, and the company aims to redefine pain management alternatives alongside its other non-opioid treatments in development. Scilex is also expanding its pipeline with plans for further clinical trials in the near future.
Read more →SCLXScilex Holding Company Announces Issuance of a Second New Patent in the U.S. for Its Lead Commercial Product ZTlido (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Non-Aqueous Lidocaine-Containing Patch
Scilex Holding Company has announced the issuance of a second patent from the U.S. Patent and Trademark Office for its lead product, ZTlido, a lidocaine topical system designed for pain relief. This new patent, which covers a specific non-aqueous lidocaine patch, further solidifies Scilex's intellectual property position and will contribute to the commercialization efforts for ZTlido, set to expire in 2031. The two patents will also be listed in the FDA's Orange Book, aligning with Scilex’s strategy to enhance its market presence in non-opioid pain management solutions.
Read more →SCLXScilex Holding Company Announces Issuance of New Patent in the U.S. for Its Lead Commercial Product ZTlido (lidocaine topical system) for a Method of Relieving Pain Through the Application of a Lidocaine-Containing Patch
Scilex Holding Company has announced the issuance of a new patent by the U.S. Patent and Trademark Office for its lead product, ZTlido, which is a lidocaine topical system designed for pain relief. The patent strengthens the company's intellectual property position and highlights its dedication to non-opioid pain management solutions. CEO Jaisim Shah emphasized the company's commitment to developing differentiated programs targeting unmet needs in pain management, indicating confidence in future growth opportunities for ZTlido. The company continues to expand its portfolio of non-opioid therapies aimed at improving patient outcomes.
Read more →SCLXScilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica)
Scilex Holding Company announced a favorable outcome from their recent Type C meeting with the FDA regarding SP-102, a treatment for Lumbosacral Radicular Pain (sciatica). The FDA guided the company on the requirements to file a New Drug Application (NDA), which includes conducting a multi-center safety and efficacy trial starting in early 2024. This marks a significant step for Scilex towards advancing the registration of SP-102, which, if approved, would be the first injectable corticosteroid for epidural administration in the U.S. The company plans to enroll approximately 700 patients for this upcoming trial.
Read more →SCLXScilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido , in Treatment of Musculoskeletal Pain Disorders
Scilex Holding Company has announced new data from studies on SP-103, a lidocaine topical system for treating musculoskeletal pain disorders. Results indicate that SP-103 provides a significantly higher concentration of lidocaine in muscle tissue compared to ZTlido. The data, presented at the AAPS 2023 meeting, supports the effectiveness of SP-103 in delivering treatment for localized pain and suggests potential expansion of its indications. These findings align with Scilex's ongoing clinical development plans for SP-103.
Read more →SCLXScilex Holding Company Generates Record Monthly Revenue In October 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended October 2023, And Year-To-Date Through October 31, 2023, Based On Currently Available Information
Scilex Holding Company has announced impressive financial results for October 2023, reporting record gross sales for its product ZTlido, estimated at between $14.5 million to $15.5 million. Year-to-date gross sales through October 2023 also show significant growth of 47% to 60% compared to the previous year. The net sales for October 2023 reached between $4.0 million to $5.0 million, highlighting a stable increase in revenue. Furthermore, Scilex is poised for future growth with plans to initiate Phase 2/3 trials for chronic neck pain in 2024 and expand its product offerings.
Read more →SCLXScilex Holding Company Files Emergency Motion in the United States Bankruptcy Court for the Southern District of Texas for Entry of an Order Compelling the Production of Books and Records from certain Brokers, Dealers, Banks and other Nominees Pursuant to Rule 2004 of the Federal Rules of Bankruptcy Procedure
Scilex Holding Company has filed an emergency motion in the U.S. Bankruptcy Court for the Southern District of Texas, seeking to compel the production of financial records from various financial entities. This move comes amidst ongoing proposals to short sellers regarding their positions in Scilex's stock. The company has faced challenges in managing its financial obligations while also planning several clinical trials for its product candidates. Scilex continues to pursue its objective of leading in non-opioid pain management, despite evident financial difficulties.
Read more →SCLX▲ +15.9%on this news· ran to +32% by day 1
Scilex Holding Company Retains Warshaw Burstein, LLP and Christian Attar Law to Investigate Potential Naked Short Selling, Short Positions, Stock Lending Program Activities and Market Manipulation of Its Stock Price
Scilex Holding Company has retained Warshaw Burstein, LLP and Christian Attar Law to investigate potential instances of naked short selling and market manipulation concerning its stock price. The investigation follows announcements of two settlement proposals aimed at short sellers and lenders involved with Scilex's restricted shares. The company expresses concerns about targeted stock manipulation efforts that may adversely affect its shares' market value. Scilex aims to hold those responsible accountable and protect the interests of its investors.
Read more →SCLX▲ +11.9%on this news· ran to +44% by day 3shared move
Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted Dividend Shares of Scilex Holding Company
Scilex Holding Company has announced a proposal for lenders of short positions in its restricted dividend shares, allowing them to cover their positions without incurring additional costs. This comes after significant progress made in settling with other short sellers, whereby around 800,000 short positions have been closed. The proposal is designed to address ongoing issues of naked short selling, with an emphasis on regulatory compliance and financial clarity. Interested lenders have a deadline of October 31, 2023, to participate in this offer.
Read more →SCLX▼ -5.3%on this news· ran to +18% by day 3shared move
Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company
Scilex Holding Company announced a notice to record holders and beneficial owners of restricted shares following a dividend from Sorrento Therapeutics. This dividend, comprising 76 million shares, faces transfer restrictions until March 31, 2024. In the context of Sorrento's Chapter 11 bankruptcy, Scilex has proposed a resolution for short sellers involved in illegal naked short selling, allowing them to purchase shares in the open market to cover their positions. The proposal, commencing on October 6 and ending by October 27, 2023, aims to facilitate compliance and release claims against Scilex.
Read more →SCLXScilex Holding Company Submits a Request to the Securities and Exchange Commission to Withdraw its Registration Statement on Form S-1 (File No. 333-271401)
Scilex Holding Company has submitted a request to the SEC to withdraw its Registration Statement on Form S-1 initially filed in April 2023. This action comes as the Registration Statement had not yet been declared effective, and no securities had been sold under it. Scilex remains focused on its development of non-opioid pain management products and has a pipeline that includes drugs in various clinical phases. The company anticipates that the SEC will grant the request unless notified otherwise within 15 days.
Read more →SCLXScilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023
Scilex Holding Company announced that the State of Indiana Medicaid will add its product, Elyxyb, to its Preferred Drug List (PDL) effective October 1, 2023. This move is expected to enhance access to Elyxyb for approximately 1.2 million eligible Medicaid patients in Indiana. The preferred status includes specific prior authorization criteria aimed at patients with migraine diagnosis aged 18 or older. Scilex's CEO emphasized the importance of this advancement in expanding Elyxyb's utilization and promoting non-opioid pain management solutions.
Read more →SCLXScilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.
Scilex Holding Company has successfully completed the purchase of all common and preferred shares, as well as warrants owned by Sorrento Therapeutics. The acquisition includes a total cash consideration of $10 million and the assumption of approximately $100 million in Sorrento's debt. This strategic move emphasizes Scilex's commitment to expand its innovative non-opioid pain management products. However, the deal also involves significant financial liabilities, which may pose risks to Scilex's future operations.
Read more →SCLXScilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido , Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)
Scilex Holding Company has completed its Phase 2 trial for SP-103, a lidocaine topical system, aimed at evaluating its safety and efficacy in treating moderate to severe acute lower back pain. The trial, which enrolled 75 patients, showed promising results with no serious adverse events and a meaningful reduction in pain for specific patient subpopulations. Following this achievement, Scilex is analyzing the data to inform future studies and potential indications for product registration. The company is optimistic about the implications for SP-103 in the pain management market, particularly given the high prevalence of lower back pain among adults in the U.S.
Read more →SCLX▼ -8.6%on this news· ran to -19% by day 3shared move
Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
Scilex Holding Company has entered non-binding term sheets to acquire all shares and warrants owned by Sorrento Therapeutics. This decision follows a hearing where the Bankruptcy Court approved the Scilex Term Sheets, allowing for a swift completion anticipated by September 19, 2023. The total acquisition consideration amounts to approximately $110 million, alongside the assumption of certain debts. This strategic move aims to bolster Scilex's position in the pain management sector.
Read more →SCLXScilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV
Scilex Holding Company presented findings on ZTlido at the 2023 PAINWeek Conference in Las Vegas, NV. The presentations highlighted the advantages of ZTlido, including its improved adhesion and decreased healthcare resource utilization compared to traditional lidocaine patches. These findings suggest that ZTlido may offer better efficacy with fewer side effects for neuropathic pain management. The data underscores Scilex's commitment to advancing non-opioid pain management solutions.
Read more →SCLX▼ -5.1%on this newsshared move
Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available Information
Scilex Holding Company reported record gross sales of ZTlido for August 2023, estimating gross sales between $13.0 million and $14.0 million, a notable increase compared to the previous year. The company also provided preliminary unaudited financial results, highlighting significant growth in both gross and net sales year-to-date. However, these figures remain subject to audit, and actual results may vary. Scilex continues to focus on developing and marketing non-opioid pain management products, with several upcoming products scheduled for commercialization.
Read more →SCLX▼ -5.1%on this newsshared move
Execution Version NON-BINDING
Scilex has been named the winning bidder for a Securities Transfer, proposing a purchase price of $110 million. The term sheet outlines structured transactions but remains non-binding, pending approval from relevant parties including the Bankruptcy Court. Concerns have been raised about closing conditions and the commitment of Hudson Bay to fund the transaction. The finalization of agreements is also subjected to board approvals, creating further uncertainty.
Read more →SCLX▲ +10.2%on this news
Scilex Holding Company Announces Results From Independent Market Research Study Conducted with Pain Specialists and HCPs Treating Post-Herpetic Neuralgia (PHN) Pain on ZTlido
Scilex Holding Company (SCLX) has announced positive results from an independent market research study conducted with pain specialists regarding its lidocaine patch, ZTlido®. The study indicates a growing awareness among healthcare providers and a substantial intent to prescribe ZTlido®, which is expected to lead to increased utilization. ZTlido® is projected to achieve peak sales exceeding $500 million in the next six years, with recent data showing significant growth in new and total prescriptions. The company aims to position itself favorably in the non-opioid pain management market, reflecting its commitment to treating post-herpetic neuralgia.
Read more →SCLXScilex Holding Company Generates Record Monthly Revenue In June 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended June 2023, Quarter Ended June 2023, And Year-To-Date As Of June 2023, Based On Currently Available Information
Scilex Holding Company reported record revenue figures for June 2023, with gross sales reaching approximately $13.5 million to $14.5 million, marking an increase of 82% to 96% compared to the same month in the previous year. The preliminary financial results also indicate substantial growth in net sales, with year-to-date gross sales estimated between $64.2 million and $67.3 million. While the company expresses confidence in its future growth, it also acknowledges that actual results may vary from the preliminary estimates.
Read more →SCLXSafe Harbor Statements Forward-Looking Statements Certain statements contained in this corporate presentation (this "Presentation"), along with certain statements that may be made by management of Scilex Holding Company
Scilex Holding Company is making strides in the pharmaceutical industry with innovative non-opioid pain management products. The company recently positioned itself with successful launches of FDA-approved treatments, such as Elyxyb and the upcoming Gloperba for gout. Scilex's revenue report shows a 21% year-over-year growth, reflecting positive market reception. Additionally, the company's pipeline includes multiple candidates in various stages of development, indicating ongoing commitment to addressing significant health needs in pain management.
Read more →SCLXScilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX.
Scilex Holding Company announced it will present clinical data on ELYXYB™ (celecoxib oral solution) aimed at treating migraines at the 65th Annual Scientific Meeting of the American Headache Society. This presentation, scheduled for June 16, 2023, will be led by Dr. Stuart J. Tepper and focuses on pivotal studies regarding the drug's effectiveness. ELYXYB™ is the only FDA-approved ready-to-use oral solution for acute migraine treatment, and Scilex aims to position itself as a leader in non-opioid pain management solutions.
Read more →SCLXScilex Holding Company Announces that Sorrento Therapeutics, Inc.’s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock
Scilex Holding Company announced that the U.S. Bankruptcy Court for the Southern District of Texas issued a temporary restraining order against short-sales of its common stock amidst Sorrento Therapeutics' chapter 11 bankruptcy proceedings. This order aims to prevent any further market volatility linked to short-selling and mandates brokerage firms to account for profits from such activities. A hearing is scheduled for June 27, 2023, to discuss a preliminary injunction on these matters. The order reflects the concerns of the Official Committee of Equity Security Holders, representing the interests of Sorrento stockholders.
Read more →SCLXScilex Holding Company provides certain preliminary unaudited financial results for gross and net Sales for the one month ended May 2023, and year-to-date May 2023, based on currently available information
Scilex Holding Company has released preliminary unaudited financial results for May 2023 and year-to-date results, highlighting a significant increase in both gross and net sales compared to the same period in 2022. Gross sales for May 2023 are estimated to be between $13.0 million and $15.0 million, reflecting growth of 53% to 76%. Year-to-date gross sales also show substantial growth, with projections indicating increases of 54% to 70% over the prior year. However, these results have not been audited, and actual figures may vary significantly from these estimates.
Read more →SCLXScilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (“CHT” or “Territories Distributor”) and Farouk, Maamoun Tamer & Co. (“Master Distributor”) For the Distribution of ZTlido in the Kingdom of Saudi Arabia
Scilex Holding Company has entered a master distributor agreement with Farouk, Maamoun Tamer & Co. for the distribution of its non-opioid pain management product ZTlido in Saudi Arabia. This collaboration aims to expand Scilex's reach across the Middle East and North African markets, offering a significant alternative to opioid medications. ZTlido is designed to address neuropathic pain with improved adhesion and continuous relief. The partnership represents a strategic step for Scilex in navigating the complex regulatory environment while responding to the rising demand for non-opioid therapies.
Read more →SCLXScilex Holding Company Added to the Preliminary List of the Russell 3000 Index and the Small-Cap Russell 2000 Index as part of the 2023 Russell Indexes Annual Reconstitution in June 2023
Scilex Holding Company has been added to the preliminary list of the Russell 3000 Index and the Small-Cap Russell 2000 Index as part of the 2023 annual reconstitution. This inclusion reflects the company's growth and market position in non-opioid pain management. The final membership will be determined after the market closes on June 23, 2023. Company executives believe this recognition will enhance visibility and attract investment to support their ongoing clinical development and commercialization efforts.
Read more →SCLXScilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido , for the Treatment of Acute Low Back Pain
Scilex Holding Company has announced the complete enrollment of its Phase 2 study for SP-103, a lidocaine topical system aimed at treating acute low back pain. This randomized, double-blind study will evaluate the drug’s safety and efficacy in approximately 80 patients across 10 sites in the U.S., with top-line data expected in Q3-2023. SP-103, which received Fast Track designation from the FDA, aims to provide an effective non-opioid option for pain management, addressing a significant market need given that 25% of U.S. adults suffer from acute low back pain.
Read more →SCLXScilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023
Scilex Holding Company announced its participation in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023. Key executives, including Dr. Henry Ji and Jaisim Shah, will engage in a CEO fireside chat format and hold 1x1 meetings with investors. Scilex focuses on developing and commercializing non-opioid pain management solutions, with several products in its pipeline and recent FDA-approved product launches. The conference is expected to enhance Scilex's visibility among investors and stakeholders.
Read more →SCLXScilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Notice that Sorrento’s Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Distributed by Sorrento to its Stockholders as a Dividend
Scilex Holding Company announced that Sorrento Therapeutics, its majority stockholder, has extended the lockup period on shares distributed to stockholders as a dividend. The U.S. Bankruptcy Court for the Southern District of Texas has pushed the expiration of these restrictions from May 11, 2023, to September 1, 2023. This decision impacts only the Distributed Stock and may affect shareholders' ability to sell or transfer their shares during this period. The extension comes amidst ongoing bankruptcy proceedings for Sorrento Therapeutics.
Read more →SCLXScilex Holding Company Enters into Master Distributor Agreement with CH Trading Group LLC and AD Ports Group for the Distribution of ZTlido in the Middle East and North Africa Region
Scilex Holding Company has announced a master distributor agreement with CH Trading Group LLC and AD Ports Group for the distribution of its product ZTlido in the Middle East and North Africa region. The agreement targets several countries, including the United Arab Emirates, Qatar, and Egypt, allowing for expanded commercialization of non-opioid pain management solutions. This partnership is expected to leverage advanced logistical capabilities to improve access to innovative pain management products in the region, reinforcing Abu Dhabi's vision as a hub for healthcare and life sciences.
Read more →SCLXScilex Holding Company Announces Final Postponement of Annual Meeting of Stockholders
Scilex Holding Company has postponed its 2023 Annual Meeting of Stockholders from April 17 to May 4, 2023. This delay is attributed to the underreporting of over 44 million shares of common stock, which needs to be rectified by brokerage firms as per a U.S. Bankruptcy Court order linked to Sorrento Therapeutics' chapter 11 proceedings. The company anticipates that compliance with the court's orders will allow these shares to participate in the upcoming meeting. The situation has raised concerns about corporate governance and stockholder engagement during a time of regulatory scrutiny.
Read more →SCLXScilex Holding Company Announces Postponement of Annual Meeting of Stockholders
Scilex Holding Company has announced the postponement of its 2023 Annual Meeting of Stockholders from April 6 to April 17, 2023. This decision follows a court order requiring brokerage firms to provide reports concerning the record and beneficial ownership of Scilex's common stock, as there was significant underreporting. Scilex expects that compliance with this court order will allow more shares to participate in the meeting, although uncertainties remain due to ongoing bankruptcy proceedings. This adjustment reflects the company's commitment to ensuring accurate and complete stockholder representation.
Read more →SCLXScilex Holding Company Reports Substantial Underreporting of More Than 44 Million Shares of its Common Stock by Brokerage Firms for the Upcoming Annual Meeting of Stockholders Scheduled for April 6, 2023 and Issues a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
Scilex Holding Company has reported that over 44 million shares of its common stock have not been reported by brokerage firms ahead of the Annual Meeting scheduled for April 6, 2023. This substantial underreporting presents risks of legal challenges, as it violates stockholder voting rights under Delaware law. The company believes that brokerage firms have failed in their obligation to deliver proxy materials to stockholders, which may lead to government investigations and sanctions. Scilex is coordinating with regulatory agencies and urging stockholders to demand their voting rights be respected.
Read more →SCLXScilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products
Scilex Holding Company has announced a financing agreement to raise up to $25 million to support the commercialization of its three FDA-approved non-opioid pain management products: ZTlido®, Gloperba®, and ELYXYB™. This financing will be executed through a series of convertible debentures and is aimed at enhancing the launch of these innovative products in major markets. The company's CEO highlighted the need for better pain management solutions, emphasizing that current options often fall short in providing effective pain relief.
Read more →SCLXScilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment
Scilex Holding Company has entered into a distribution agreement with CH Trading Group to commercialize its ZTlido product in the Middle East and North Africa. This agreement includes a minimum purchase commitment of $105 million over the next five years, allowing for the potential expansion of Scilex’s non-opioid pain management portfolio. The collaboration emphasizes Scilex's strategy to penetrate new markets, aiming to meet growing demand for innovative pain management solutions. ZTlido is a lidocaine topical system designed specifically to alleviate neuropathic pain effectively.
Read more →SCLXScilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management
Scilex Holding Company has announced the commercial launch of ELYXYBTM, an FDA-approved oral solution for the acute treatment of migraines in adults. This product is positioned to enhance Scilex's leadership in non-opioid pain management and diversify its revenue streams. The launch is supported by extensive promotional efforts and an experienced sales team dedicated to marketing the product. ELYXYBTM is expected to provide substantial synergies and contribute positively to the company's cash flow and earnings.
Read more →SCLXScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine
Scilex Holding Company has acquired the rights to ELYXYB™, the only FDA-approved oral solution for the acute treatment of migraine in adults, in the U.S. and Canada. This strategic acquisition positions Scilex to enhance its non-opioid pain management offerings and expand its market presence. With the acute migraine drug market expected to grow significantly, Scilex aims to leverage its experienced commercial team to effectively distribute ELYXYB™. The drug has demonstrated rapid onset of action and safety, making it a key addition to Scilex's portfolio alongside its existing pain management products.
Read more →SCLXScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders
Scilex Holding Company, a subsidiary of Sorrento Therapeutics, has announced its first virtual Annual Meeting of Stockholders to be held on April 6, 2023. The record date for stockholder eligibility is set for March 6, 2023. Scilex focuses on developing non-opioid pain management products, with several promising candidates in its pipeline. The company aims to become a leader in the pain management market, emphasizing its commitment to responsible product development.
Read more →SCLXScilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
Scilex Holding Company announced that its majority stockholder, Sorrento Therapeutics, has issued a supplement to its Frequently Asked Questions regarding the common stock dividend. The update addresses the removal of contra-CUSIP by the Depository Trust and Clearing Corporation, ensuring that shares now reflect only Scilex's CUSIP number. This communication aims to assist brokerage firms and shareholders with the dividend process, reiterating key details for those affected by short positions in Sorrento stock.
Read more →SCLXScilex Holding Company Announces that its Majority Stockholder, Sorrento Therapeutics, Inc., has Issued an “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
Scilex Holding Company announced that its majority stockholder, Sorrento Therapeutics, Inc., has published a "Frequently Asked Questions" document. This document details important information regarding a recent dividend of shares in Scilex common stock. Key topics include the record date, payment date, distribution method, and implications for stockholders. The transparency provided by Sorrento aims to assist stockholders in understanding their dividend entitlements.
Read more →SCLXNote to Stockholders of Scilex Holding Company ( Scilex ): In connection with the dividend by Scilex s controlling stockholder, Sorrento Therapeutics, Inc. ( Sorrento ), of shares of Scilex common stock held by Sorrento,
Sorrento Therapeutics has issued a supplement regarding the dividend of common stock from Scilex Holding Company. This communication is intended to clarify details around the dividend and ensure investors receive accurate information. Several major brokerage firms have confirmed the processing of Scilex shares into the accounts of eligible shareholders. The update also includes changes in the CUSIP number for Dividend Stock, emphasizing the importance for shareholders to verify their statements with their respective brokerage firms.
Read more →SCLXScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento ), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination Approximat
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento ), and Vickers Vantage Corp. I Announce the Closing of their Previously Announced Business Combination PALO ALTO and NEW YORK, November 10, 2022 /Newswire/ Scilex Holding
Read more →SCLXScilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on Form S-4, Date of Vickers Vantage Extraordinary General Meeting to Approve Proposed Business Combination
SEC declared Effectiveness of Vickers’s registration statement on Form S-4 Extraordinary General Meeting of Vickers Vantage Corp. I shareholders to approve the proposed Business Combination is scheduled to be held on November 9, 2022, at 10:00 a.m., Eastern Time Post-closing co
Read more →SCLXScilex Holding Company, a Sorrento Company, Announces Pre-Emptive Pay Off of Remaining Balance of its Senior Secured Notes
PALO ALTO, Calif. and SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, to
Read more →SCLXScilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido , for the Treatment of Acute Low Back Pain (LBP)
SP-103 receives Fast Track Designation, which makes it eligible for some or all of the following: More frequent meetings or written communication with the FDA to discuss the SP-103 development plan and ensure collection of appropriate data needed to support drug approval. Eligi
Read more →SCLXScilex Holding Company, a Sorrento Company, Announces Exclusive Product Distribution Agreement with CH Trading Group LLC to Expand Commercialization of ZTlido across certain designated territories including Middle East and North Africa
PALO ALTO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, today announced the signing of a Product Distrib
Read more →SCLXScilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc.
Ancora Medical Inc. (“Ancora”) is a privately held medical technology company with an FDA approved product in February 2020, the Nerve Block Catheter Set which is indicated for surgical pain management during the pre-operative, perioperative and post-operative periods associated
Read more →SCLXScilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors
PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializ
Read more →SCLXVickers Vantage Corp. I Announces Shareholder Approval of Extension of Deadline to Complete Business Combination
Vickers Vantage Corp. I Announces Shareholder Approval of Extension of Deadline to Complete Business Combination YORK, NY, July 5, 2022 /Newswire/ -- Vickers Vantage Corp. I (NASDAQ: VCKAU, VCKA, VCKAW) ("Vickers"), a special purpose acquisition company, announced today that o
Read more →SCLXScilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba , an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.
Gloperba is an FDA-approved, oral medication for treating painful gout flares in adults. Gout is a painful arthritic disorder affecting an estimated 8.7 million people in the United States1. As gout cases increase every year, treatment requirements increase. The gout treatment m
Read more →SCLXScilex Holding Company, a Sorrento Company, Announces Pre-Emptive Repurchase of $41.4 Million of its Senior Secured Notes
SAN DIEGO and PALO ALTO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing an
Read more →SCLXScilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the previously announced proposed business combination between Scilex and Vickers
PALO ALTO, Calif. and NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”) and Vickers Vantage Corp. I (Nasdaq: VCKA “Vicker
Read more →SCLXScilex Holding Company a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., Appoints Highly Accomplished Life Science Executive, Elizabeth Czerepak, as Executive Vice President, Chief Financial Officer (CFO) and Chief Business Officer (CBO)
SAN DIEGO and PALO ALTO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), who is a commercial biopharmaceutical company focused on devel
Read more →SCLXScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Expanding Its Direct Distribution Network to National And Regional Wholesalers And Pharmacies
PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commerciali
Read more →SCLXScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill
PALO ALTO, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commerciali
Read more →SCLXVICKERS VANTAGE CORP. I
VANTAGE CORP. I EXTENDS TIME TO COMPLETE BUSINESS COMBINATION YORK, NY, April 11, 2022 (GLOBE NEWSWIRE) -- Vickers Vantage Corp. I (Nasdaq: VCKAU, VCKA, VCKAW) ("Vickers" or the "Company"), a Cayman Islands exempted company, announced today that it has further extended the time
Read more →SCLXScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido with preliminary gross sales of approximately $8.1 million during the month of March 2022 and $18.4 million for 1Q2022
ZTlido 53% year-over-year preliminary unaudited gross sales in March 2022 Select payor accounts representing approximately 200 million of the over 300 million covered lives across the United States PALO ALTO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“S
Read more →SCLXScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage Corp I
PALO ALTO, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies fo
Read more →SCLXScilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for First to Market Opportunity
SP-102 (SEMDEXA™), with 401 patients enrolled in the C.L.E.A.R. trial (Corticosteroid Lumbosacral Epidural Analgesia in Radiculopathy), experienced a rapid onset of pain relief, measured by Numeric Pain Rating Scale of average daily pain in the affected leg, with highly statistic
Read more →SCLXC C on on f f i i den de t nt i i al al : : F F or or I In nt te er r na na l l S S C C I I L E LE X X P P h ha a r r m m a c a c e u t eu t i i c c a l a l s s U U s s e e O n On l l y y 1 1 Scilex Holding Company Innov
C C on on f f i i den de t nt i i al al : : F F or or I In nt te er r na na l l S S C C I I L E LE X X P P h ha a r r m m a c a c e u t eu t i i c c a l a l s s U U s s e e O n On l l y y 1 1 Scilex Holding Company Innovative Leader in Non - Opioid Pain Therapeutics D ece m be r
Read more →SCLXScilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management Supporting the Potential Use of SP-102 as a Best-in-Class Therapy
Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announces highly significant positive top-line results from its Phase 3 SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R Program for its novel, non-opioid, corticosteroid formulation, injec
Read more →SCLXScilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (“SPAC”) Enter into Letter of Intent for Proposed Business Combination
Scilex Holding Company (Scilex) a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), and Vickers Vantage Corp I (Nasdaq: VCKA) announce signing of a letter of intent for a proposed business combination, which provides for a pre-transaction equity value of Scilex of approxi
Read more →SCLXScilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido Managed Care Coverage for Additional 33 Million Lives
PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), announced that, effective September 1, 2021, ZTlido® (lidocaine topical system) 1.8% has been added to multiple formularies, including
Read more →SCLXScilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management
Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announced complete enrollment of its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program for its novel, non-opioid, corticosteroid formulation, injectable dexamethasone sodium
Read more →SCLXVickers VANTAGE CORP. I RECEIVES NASDAQ NOTIFICATION OF NON-COMPLIANCE
VANTAGE CORP. I RECEIVES NASDAQ NOTIFICATION OF NON-COMPLIANCE WITH LISTING RULES SINGAPORE - June 1, 2021 - VICKERS VANTAGE CORP. I (NASDAQ: VCKA) ("Vickers" or the "Company"), a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisiti
Read more →SCLXVICKERS VANTAGE CORP. I INDEX TO FINANCIAL STATEMENT Page Audited Financial Statements of Vickers Vantage Corp. I: Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
VICKERS VANTAGE CORP. I INDEX TO FINANCIAL STATEMENT Page Audited Financial Statements of Vickers Vantage Corp. I: Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of January 11, 2021 F-3 Notes to Financial Statement F-4 Report of Independent
Read more →SCLXVickers Vantage Corp. I Announces Pricing of Upsized $120,000,000 Initial Public Offering
Vickers Vantage Corp. I Announces Pricing of Upsized $120,000,000 Initial Public Offering NEW YORK, January 6, 2021-(BUSINESS WIRE)-Vickers Vantage Corp. I (the "Company") announced today that it priced its initial public offering of 12,000,000 units at $10.00 per unit. The u
Read more →SCLXScilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020
Preliminary Q3 2020 net sales of ZTlido® of approximately $7.2 million, quarter-over-quarter growth of 26% compared to $5.7MM in Q2-2020 despite the continued impact of COVID-19 pandemic. The Phase 3 pivotal trial investigating SP-102 non-opioid therapy for lumbosacral radicular
Read more →SCLXScilex Announces New Medicaid Agreements with CA & FL
PALO ALTO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), is excited to announce that its subsidiary, Scilex Pharmaceuticals, Inc., (together, with Scilex Holding Company, “Scil
Read more →SCLXScilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak
PALO ALTO, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors in May of this year. Dr. Whitcup is founder and Chief Executive Officer of Akrivis
Read more →Competitive Position
How SCLX ranks across every disease it competes inCompetitive Position is a premium feature
See how SCLX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial